

Disclaimer

The following report(s) provides findings from an FDA-initiated query using its Mini-Sentinel pilot. While Mini-Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Mini-Sentinel, and seeking to better understand the capabilities of the Mini-Sentinel pilot.

Data obtained through Mini-Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Mini-Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview for Request to16_cap_mpl1r_wp022_nsdv_v01, Report 2 of 2

Request ID: to16_cap_mpl1r_wp022_nsdv_v01. This is Report 2 of 2.

Query Description: The Opioid Analgesics Prescribing Trends Workgroup has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool, version 2.0.7, to find estimates of the percentage of extended-release (ER) oxycodone users who have a drug screen in the month prior to oxycodone use or in the six months after oxycodone use. The query was run against the Mini-Sentinel Distributed Database (MSDD) for the time period of January 1, 2009 to December 31, 2013. The request was distributed to 15 Data Partners on July 29, 2015. This report contains results for ER oxycodone. Report 1 contains results for extended-release and long-acting (ER/LA) opioid analgesics.

Study Design: This request was designed to identify exposures with and without drug screens in the month prior or within six months after opioid initiation. The number of exposure episodes in the MSDD was calculated overall and were stratified by age group, sex, and year.

Exposure of Interest: The exposure of interest was extended-release (ER) oxycodone. See Appendix A for specific codes.

Cohort Eligibility Criteria: Those included in the cohort were required to be continuously enrolled in plans with both medical and drug coverage for at least six months (183 days) before their exposure date, during which gaps in coverage of up to 45 days were allowed. The following age groups were included in the cohort: 0-11, 12-17, 18-24, 25-34, 35-44, 45-54, and 55-64 years. The cohort includes patients who used ER oxycodone for at least one day, with an outpatient pharmacy dispensing days supplied of at least one day. All qualifying incident exposure episodes per patient that occurred between January 1, 2009 and December 31, 2013 were examined. Individuals with an opioid poisoning diagnosis within six months (183 days) prior to the date of exposure were excluded from the cohort (please see Appendix D for specific codes). Individuals were also required to have no evidence of any ER/LA opioid (see Appendix B for specific codes) in the six months (183 days) prior to the dispensing of the drug of interest.

Sensitivity Analyses: Three sensitivity analyses were conducted for the cohort and each cohort subset described above:

- 1) The first sensitivity analysis was designed to capture long-term and chronic opioid users of ER oxycodone. Chronic use is defined as an exposure episode with at least 12 weeks (84 days) supplied for ER oxycodone outpatient pharmacy dispensings. Exposure episodes were created with the following methods:
 - a. Multiple drug dispensings were considered part of the same exposure episode if the end of the days supplied for the first dispensing and the next dispensing were less than 10 days apart.
 - b. Multiple drug dispensings with the same generic name and dose occurring on the same day used the maximum days supplied value and added together the amount supplied values of each dispensing.
 - c. If two dispensings with the same generic name and dose overlapped, any overlap of supply between dispensing was corrected by pushing overlapping days supplied forward.
- 2) The second sensitivity analysis was designed to examine a less strict definition of cohort eligibility, in which individuals were required to be continuously enrolled in plans with both medical and drug coverage for at least three months (90 days) before their dispensing date, during which gaps in coverage of up to 45 days were allowed. Individuals were also required to have no evidence of any ER/LA opioid in the three months (90 days) prior to the dispensing of the drug of interest. In addition to the main analysis, this sensitivity analysis was combined with the first sensitivity analysis to apply a less strict cohort eligibility definition to chronic users.
- 3) The third sensitivity analysis was designed to stratify by evidence of an immediate release (IR) opioid prescription within two months to one day before the date of exposure (please see Appendix D for specific codes). Due to programmatic restrictions, IR opioid use was set up as an exclusion; however, the output has been used to calculate the number of users who did have an IR opioid prescription within two months prior to exposure, which is displayed in Tables 1-4 (complete results for each cohort are displayed in the Appendices for Tables 1- 4). In addition to the main analysis, this sensitivity analysis was combined with all other sensitivity analyses.

Please see Appendix E for the specifications of parameters used in the analyses for this request.

Limitations: Algorithms to define exposures, exclusion criteria, and outcomes are imperfect and, therefore, may be misclassified.

Notes: Please contact the Sentinel Operations Center Query Fulfillment Team (qf@sentinelinitiative.org) for questions and to provide comments/suggestions for future enhancements to this document.

Table of Contents

<u>Glossary</u>	List of Terms Found in this Report and their Definitions
<u>Table 1</u>	Percentage of New Extended-Release Oxycodone Users and Episodes with Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, and Evidence of Prior Immediate Release (IR) Opioid Use
<u>Appendix Table 1</u>	Summary of Extended-Release (ER) Oxycodone Use and Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Immediate Release (IR) Exclusion Requirement, and Drug Screen Inclusion Requirement
<u>Appendix Table 2</u>	Summary of Extended-Release (ER) Oxycodone Use and Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Immediate Release (IR) Exclusion Requirement, Drug Screen Inclusion Requirement, and Age Group
<u>Table 2</u>	Percentage of New Extended-Release Oxycodone Users and Episodes with Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Evidence of Prior Immediate Release (IR) Opioid Use, and Age Group
<u>Table 3</u>	Percentage of New Extended-Release Oxycodone Users and Episodes with Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Evidence of Prior Immediate Release (IR) Opioid Use, and Sex
<u>Appendix Table 3</u>	Summary of Extended-Release (ER) Oxycodone Use and Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Immediate Release (IR) Exclusion Requirement, Drug Screen Inclusion Requirement, and Sex
<u>Table 4</u>	Percentage of New Extended-Release Oxycodone Users and Episodes with Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Evidence of Prior Immediate Release (IR) Opioid Use, and Year
<u>Appendix Table 4</u>	Summary of Extended-Release (ER) Oxycodone Use and Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Immediate Release (IR) Exclusion Requirement, Drug Screen Inclusion Requirement, and Year
<u>Appendix A</u>	List of Drugs used for Exposures in this Request
<u>Appendix B</u>	List of Drugs used for Incidence Assessment Criteria in this Request
<u>Appendix C</u>	List of Healthcare Common Procedure Coding System (HCPCS) and Current Procedural Terminology (CPT) Procedure Codes used for Drug Screens in this Request
<u>Appendix D1</u>	List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) Diagnosis Codes used for Exclusions in this Request
<u>Appendix D2</u>	List of Drugs used for Inclusions/Exclusions in this Request
<u>Appendix E</u>	Specifications for Opioid Analgesics Prescribing Trends: Drug Screen Metrics (to16_cap_mpl1r_wp022_nsdp_v01)
<u>Appendix F</u>	List of Dates of Available Data for Each Data Partner as of Request Send Date (July 29, 2015)

Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Tool*

- Amount Supplied** - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing. This is equivalent to the
- Blackout Period** - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.
- Care Setting** - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). Along with the Principal Diagnosis Indicator, forms the Care Setting/PDX parameter.
- Cohort Definition (drug/exposure)**- indicates how the cohort will be defined: (1) 01: Cohort includes only the first valid incident treatment episode during the query period; (2) 02: Cohort includes all valid incident treatment episodes during the query period; (3) 03: Cohort includes all valid incident treatment episodes during the query period until an event occurs.
- Days Supplied** - number of days supplied for all dispensings in qualifying treatment episodes.
- Enrollment Gap** - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled"
- Episodes** - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged
- Episode Gap** - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the
- Event Deduplication** - specifies how events are counted by the MP algorithm: (0) 0: Counts all occurrences of an HOI during an exposure episode; (1) 1: de-duplicates occurrences of the same HOI code and code type on the same day; (2) 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).
- Exposure Extension Period** - number of days post treatment period in which the outcomes/events are counted for a treatment
- Exposure Episode Length** - number of days after exposure initiation that is considered "exposed time."
- Lookback Period (pre-existing condition)** - number of days wherein a member is required to have evidence of pre-existing condition
- Minimum Days Supplied** - specifies a minimum number of days in length of the days supplied for the episode to be considered.
- Minimum Episode Duration** - specifies a minimum number of days in length of the episode for it to be considered.
- Principal Diagnosis (PDX)** - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the
- Query Period** - period in which the modular program looks for exposures and outcomes of interest.
- Treatment Episode Truncation Indicator** - indicates whether observation of the incident query code during follow-up requires truncation of valid treatment episodes. A value of Y indicates that the treatment episodes should be truncated at the first occurrence of an incident query code. A value of N indicates that the treatment episodes should not be truncated at the occurrence of the
- Users** - number of members with exposure during the query period. Member must have no evidence of exposure(s) of interest (defined by incidence criteria) in the prior washout period. A user may only be counted once in a query period.
- Washout Period (drug/exposure)**** - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.
- Washout Period (event/outcome)**** - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.
- Years at Risk** - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

**incident treatment episodes must be incident to both the exposure and the event

Table 1: Percentage of New Extended-Release Oxycodone Users and Episodes with Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, and Evidence of Prior Immediate Release (IR) Opioid Use

	New Users	Percentage of New Users with Drug Screen	New Episodes	Percentage of New Episodes with Drug Screen
All Incident Extended-Release Oxycodone Use				
183-day Incidence Assessment Period/Enrollment Requirement				
<i>Minimum Days Supplied = 1 Day</i>				
All	200,682	N/A	210,581	N/A
Drug Screen in the Prior 30 Days	8,004	4.0%	8,088	3.8%
Drug Screen in the Following 183 Days	18,333	9.1%	18,726	8.9%
<i>Minimum Days Supplied = 84 Days</i>				
All	26,465	N/A	26,765	N/A
Drug Screen in the Prior 30 Days	3,014	11.4%	3,030	11.3%
Drug Screen in the Following 183 Days	6,710	25.4%	6,751	25.2%
90-day Incidence Assessment Period/Enrollment Requirement				
<i>Minimum Days Supplied = 1 Day</i>				
All	224,284	N/A	243,796	N/A
Drug Screen in the Prior 30 Days	9,907	4.4%	10,124	4.2%
Drug Screen in the Following 183 Days	22,601	10.1%	23,628	9.7%
<i>Minimum Days Supplied = 84 Days</i>				
All	32,566	N/A	33,421	N/A
Drug Screen in the Prior 30 Days	3,798	11.7%	3,833	11.5%
Drug Screen in the Following 183 Days	8,505	26.1%	8,613	25.8%
Incident Extended-Release Oxycodone Use with an IR Opioid Prescription in the Prior 60 Days				
183-day Incidence Assessment Period/Enrollment Requirement				
<i>Minimum Days Supplied = 1 Day</i>				
All	123,927	N/A	131,376	N/A
Drug Screen in the Prior 30 Days	6,945	5.6%	7,025	5.3%
Drug Screen in the Following 183 Days	15,805	12.8%	16,178	12.3%
<i>Minimum Days Supplied = 84 Days</i>				
All	22,980	N/A	23,256	N/A
Drug Screen in the Prior 30 Days	2,761	12.0%	2,776	11.9%
Drug Screen in the Following 183 Days	6,017	26.2%	6,056	26.0%
90-day Incidence Assessment Period/Enrollment Requirement				
<i>Minimum Days Supplied = 1 Day</i>				
All	138,614	N/A	153,313	N/A
Drug Screen in the Prior 30 Days	8,508	6.1%	8,714	5.7%
Drug Screen in the Following 183 Days	19,254	13.9%	20,211	13.2%
<i>Minimum Days Supplied = 84 Days</i>				
All	27,780	N/A	28,544	N/A
Drug Screen in the Prior 30 Days	3,436	12.4%	3,468	12.1%
Drug Screen in the Following 183 Days	7,522	27.1%	7,623	26.7%

Appendix for Table 1: Summary of Extended-Release (ER) Oxycodone Use and Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Immediate Release (IR) Exclusion Requirement, and Drug Screen Inclusion Requirement

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Eligible Members	Member-Years	New Users/1K Eligible	Days Supplied/ User	Dispensings/ User	Days Supplied/D ispending
183-day Incidence Assessment Period/Enrollment Requirement (No IR opioid use exclusion requirement)											
<i>Minimum Days Supplied = 1 Day</i>											
All	200,682	210,581	531,149	12,288,431	28,937,764	74,714,981	152,248,086.5	2.69	61.23	2.65	23.14
Drug Screen in the Prior 30 Days	8,004	8,088	44,062	1,177,668	2,746,356	N/A	N/A	N/A	147.13	5.50	26.73
Drug Screen in the Following 183 Days	18,333	18,726	97,110	2,577,939	6,130,442	N/A	N/A	N/A	140.62	5.30	26.55
<i>Minimum Days Supplied = 84 Days</i>											
All	26,465	26,765	299,272	8,442,510	20,460,394	70,340,867	140,796,647.4	0.38	319.01	11.31	28.21
Drug Screen in the Prior 30 Days	3,014	3,030	36,742	1,019,989	2,402,009	N/A	N/A	N/A	338.42	12.19	27.76
Drug Screen in the Following 183 Days	6,710	6,751	79,812	2,215,926	5,322,394	N/A	N/A	N/A	330.24	11.89	27.76
90-day Incidence Assessment Period/Enrollment Requirement (No IR opioid use exclusion requirement)											
<i>Minimum Days Supplied = 1 Day</i>											
All	224,284	243,796	638,777	15,028,442	35,682,365	81,060,908	164,985,543.2	2.77	67.01	2.85	23.53
Drug Screen in the Prior 30 Days	9,907	10,124	55,718	1,492,268	3,513,438	N/A	N/A	N/A	150.63	5.62	26.78
Drug Screen in the Following 183 Days	22,601	23,628	122,643	3,260,050	7,796,561	N/A	N/A	N/A	144.24	5.43	26.58
<i>Minimum Days Supplied = 84 Days</i>											
All	32,566	33,421	372,338	10,503,484	25,639,169	75,734,629	152,382,061.8	0.43	322.53	11.43	28.21
Drug Screen in the Prior 30 Days	3,798	3,833	46,562	1,294,288	3,076,086	N/A	N/A	N/A	340.78	12.26	27.80
Drug Screen in the Following 183 Days	8,505	8,613	100,851	2,799,190	6,758,649	N/A	N/A	N/A	329.12	11.86	27.76
183-day Incidence Assessment Period/Enrollment Requirement (IR opioid use exclusion requirement)											
<i>Minimum Days Supplied = 1 Day</i>											
All	76,755	79,205	124,713	2,230,016	5,319,572	74,037,424	144,473,502.9	1.04	29.05	1.62	17.88
Drug Screen in the Prior 30 Days	1,059	1,063	4,220	103,731	257,394	N/A	N/A	N/A	97.95	3.98	24.58
Drug Screen in the Following 183 Days	2,528	2,548	10,615	268,542	684,454	N/A	N/A	N/A	106.23	4.20	25.30
<i>Minimum Days Supplied = 84 Days</i>											
All	3,485	3,509	36,283	1,030,024	2,658,501	69,669,024	133,629,038.3	0.05	295.56	10.41	28.39
Drug Screen in the Prior 30 Days	253	254	3,084	82,682	210,208	N/A	N/A	N/A	326.81	12.19	26.81
Drug Screen in the Following 183 Days	693	695	8,049	221,179	572,948	N/A	N/A	N/A	319.16	11.61	27.48
90-day Incidence Assessment Period/Enrollment Requirement (IR opioid use exclusion requirement)											
<i>Minimum Days Supplied = 1 Day</i>											
All	85,670	90,483	150,639	2,849,312	6,916,340	80,356,374	156,577,036.2	1.07	33.26	1.76	18.91
Drug Screen in the Prior 30 Days	1,399	1,410	5,887	149,894	381,726	N/A	N/A	N/A	107.14	4.21	25.46
Drug Screen in the Following 183 Days	3,347	3,417	14,917	383,872	982,404	N/A	N/A	N/A	114.69	4.46	25.73
<i>Minimum Days Supplied = 84 Days</i>											
All	4,786	4,877	50,191	1,433,594	3,741,530	75,057,459	144,642,546.7	0.06	299.54	10.49	28.56
Drug Screen in the Prior 30 Days	362	365	4,392	121,298	315,928	N/A	N/A	N/A	335.08	12.13	27.62
Drug Screen in the Following 183 Days	983	990	11,493	318,559	826,603	N/A	N/A	N/A	324.07	11.69	27.72

Table 2: Percentage of New Extended-Release Oxycodone Users and Episodes with Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Evidence of Prior Immediate Release (IR) Opioid Use, and Age Group

	New Users	Percentage of New Users with Drug Screen	New Episodes	Percentage of New Episodes with Drug Screen
All Incident Extended-Release Oxycodone Use				
183-day Incidence Assessment Period/Enrollment Requirement				
<i>Minimum Days Supplied = 1 Day</i>				
All				
00-11 Years	161	N/A	167	N/A
12-17 Years	4,135	N/A	4,245	N/A
18-24 Years	10,746	N/A	11,108	N/A
25-34 Years	22,092	N/A	22,748	N/A
35-44 Years	35,819	N/A	37,175	N/A
45-54 Years	61,634	N/A	64,399	N/A
55-64 Years	67,331	N/A	70,739	N/A
Drug Screen in the Prior 30 Days				
00-11 Years	1	0.6%	1	0.6%
12-17 Years	27	0.7%	27	0.6%
18-24 Years	432	4.0%	434	3.9%
25-34 Years	1,312	5.9%	1,323	5.8%
35-44 Years	1,954	5.5%	1,971	5.3%
45-54 Years	2,618	4.2%	2,649	4.1%
55-64 Years	1,669	2.5%	1,683	2.4%
Drug Screen in the Following 183 Days				
00-11 Years	3	1.9%	3	1.8%
12-17 Years	84	2.0%	84	2.0%
18-24 Years	948	8.8%	966	8.7%
25-34 Years	2,997	13.6%	3,050	13.4%
35-44 Years	4,323	12.1%	4,392	11.8%
45-54 Years	5,924	9.6%	6,049	9.4%
55-64 Years	4,107	6.1%	4,182	5.9%

	New Users	Percentage of New Users with Drug Screen	New Episodes	Percentage of New Episodes with Drug Screen
Minimum Days Supplied = 84 Days				
All				
00-11 Years	1	N/A	1	N/A
12-17 Years	48	N/A	48	N/A
18-24 Years	772	N/A	779	N/A
25-34 Years	3,289	N/A	3,318	N/A
35-44 Years	5,643	N/A	5,692	N/A
45-54 Years	8,990	N/A	9,088	N/A
55-64 Years	7,768	N/A	7,839	N/A
Drug Screen in the Prior 30 Days				
00-11 Years	0	0.0%	0	0.0%
12-17 Years	3	6.3%	3	6.3%
18-24 Years	102	13.2%	102	13.1%
25-34 Years	478	14.5%	479	14.4%
35-44 Years	800	14.2%	804	14.1%
45-54 Years	1,028	11.4%	1,035	11.4%
55-64 Years	606	7.8%	607	7.7%
Drug Screen in the Following 183 Days				
00-11 Years	0	0.0%	0	0.0%
12-17 Years	7	14.6%	7	14.6%
18-24 Years	271	35.1%	273	35.0%
25-34 Years	1,127	34.3%	1,131	34.1%
35-44 Years	1,679	29.8%	1,687	29.6%
45-54 Years	2,223	24.7%	2,239	24.6%
55-64 Years	1,409	18.1%	1,414	18.0%

90-day Incidence Assessment Period/Enrollment Requirement	New Users	Percentage of New Users with Drug Screen	New Episodes	Percentage of New Episodes with Drug Screen
Minimum Days Supplied = 1 Day				
All				
00-11 Years	173	N/A	181	N/A
12-17 Years	4,447	N/A	4,638	N/A
18-24 Years	12,124	N/A	12,745	N/A
25-34 Years	25,803	N/A	27,294	N/A
35-44 Years	40,774	N/A	43,684	N/A
45-54 Years	69,102	N/A	74,886	N/A
55-64 Years	73,700	N/A	80,368	N/A
Drug Screen in the Prior 30 Days				
00-11 Years	1	0.6%	1	0.6%
12-17 Years	30	0.7%	31	0.7%
18-24 Years	514	4.2%	523	4.1%
25-34 Years	1,658	6.4%	1,685	6.2%
35-44 Years	2,450	6.0%	2,497	5.7%
45-54 Years	3,263	4.7%	3,334	4.5%
55-64 Years	2,010	2.7%	2,053	2.6%
Drug Screen in the Following 183 Days				
00-11 Years	5	2.9%	5	2.8%
12-17 Years	95	2.1%	95	2.0%
18-24 Years	1,139	9.4%	1,186	9.3%
25-34 Years	3,705	14.4%	3,841	14.1%
35-44 Years	5,397	13.2%	5,599	12.8%
45-54 Years	7,369	10.7%	7,700	10.3%
55-64 Years	4,997	6.8%	5,202	6.5%

	New Users	Percentage of New Users with Drug Screen	New Episodes	Percentage of New Episodes with Drug Screen
Minimum Days Supplied = 84 Days				
All				
00-11 Years	3	N/A	3	N/A
12-17 Years	58	N/A	59	N/A
18-24 Years	929	N/A	942	N/A
25-34 Years	4,149	N/A	4,250	N/A
35-44 Years	7,023	N/A	7,163	N/A
45-54 Years	11,139	N/A	11,410	N/A
55-64 Years	9,380	N/A	9,594	N/A
Drug Screen in the Prior 30 Days				
00-11 Years	0	0.0%	0	0.0%
12-17 Years	3	5.2%	3	5.1%
18-24 Years	118	12.7%	118	12.5%
25-34 Years	623	15.0%	626	14.7%
35-44 Years	1,024	14.6%	1,035	14.4%
45-54 Years	1,302	11.7%	1,313	11.5%
55-64 Years	733	7.8%	738	7.7%
Drug Screen in the Following 183 Days				
00-11 Years	1	33.3%	1	33.3%
12-17 Years	7	12.1%	7	11.9%
18-24 Years	324	34.9%	326	34.6%
25-34 Years	1,399	33.7%	1,409	33.2%
35-44 Years	2,155	30.7%	2,182	30.5%
45-54 Years	2,867	25.7%	2,906	25.5%
55-64 Years	1,767	18.8%	1,782	18.6%

	New Users	Percentage of New Users with Drug Screen	New Episodes	Percentage of New Episodes with Drug Screen
Incident Extended-Release Oxycodone Use with an IR Opioid Prescription in the Prior 60 Days				
183-day Incidence Assessment Period/Enrollment Requirement				
<i>Minimum Days Supplied = 1 Day</i>				
All				
00-11 Years	59	N/A	62	N/A
12-17 Years	1,153	N/A	1,193	N/A
18-24 Years	4,726	N/A	4,948	N/A
25-34 Years	13,732	N/A	14,250	N/A
35-44 Years	23,339	N/A	24,398	N/A
45-54 Years	40,103	N/A	42,222	N/A
55-64 Years	41,781	N/A	44,303	N/A
Drug Screen in the Prior 30 Days				
00-11 Years	1	1.7%	1	1.6%
12-17 Years	12	1.0%	12	1.0%
18-24 Years	284	6.0%	286	5.8%
25-34 Years	1,137	8.3%	1,148	8.1%
35-44 Years	1,745	7.5%	1,762	7.2%
45-54 Years	2,304	5.7%	2,334	5.5%
55-64 Years	1,470	3.5%	1,482	3.3%
Drug Screen in the Following 183 Days				
00-11 Years	3	5.1%	3	4.8%
12-17 Years	45	3.9%	45	3.8%
18-24 Years	662	14.0%	675	13.6%
25-34 Years	2,598	18.9%	2,650	18.6%
35-44 Years	3,827	16.4%	3,893	16.0%
45-54 Years	5,185	12.9%	5,302	12.6%
55-64 Years	3,538	8.5%	3,610	8.1%

	New Users	Percentage of New Users with Drug Screen	New Episodes	Percentage of New Episodes with Drug Screen
Minimum Days Supplied = 84 Days				
All				
00-11 Years	1	N/A	1	N/A
12-17 Years	35	N/A	35	N/A
18-24 Years	572	N/A	578	N/A
25-34 Years	2,776	N/A	2,803	N/A
35-44 Years	4,970	N/A	5,015	N/A
45-54 Years	7,887	N/A	7,977	N/A
55-64 Years	6,781	N/A	6,847	N/A
Drug Screen in the Prior 30 Days				
00-11 Years	0	0.0%	0	0.0%
12-17 Years	3	8.6%	3	8.6%
18-24 Years	79	13.8%	79	13.7%
25-34 Years	428	15.4%	429	15.3%
35-44 Years	746	15.0%	750	15.0%
45-54 Years	946	12.0%	952	11.9%
55-64 Years	562	8.3%	563	8.2%
Drug Screen in the Following 183 Days				
00-11 Years	0	0.0%	0	0.0%
12-17 Years	7	20.0%	7	20.0%
18-24 Years	207	36.2%	208	36.0%
25-34 Years	998	36.0%	1,002	35.7%
35-44 Years	1,534	30.9%	1,542	30.7%
45-54 Years	2,004	25.4%	2,019	25.3%
55-64 Years	1,273	18.8%	1,278	18.7%

90-day Incidence Assessment Period/Enrollment Requirement	New Users	Percentage of New Users with Drug Screen	New Episodes	Percentage of New Episodes with Drug Screen
<i>Minimum Days Supplied = 1 Day</i>				
All				
00-11 Years	63	N/A	68	N/A
12-17 Years	1,240	N/A	1,311	N/A
18-24 Years	5,384	N/A	5,790	N/A
25-34 Years	16,128	N/A	17,306	N/A
35-44 Years	26,713	N/A	28,996	N/A
45-54 Years	44,949	N/A	49,379	N/A
55-64 Years	45,572	N/A	50,463	N/A
Drug Screen in the Prior 30 Days				
00-11 Years	1	1.6%	1	1.5%
12-17 Years	14	1.1%	15	1.1%
18-24 Years	344	6.4%	352	6.1%
25-34 Years	1,423	8.8%	1,450	8.4%
35-44 Years	2,158	8.1%	2,205	7.6%
45-54 Years	2,849	6.3%	2,918	5.9%
55-64 Years	1,736	3.8%	1,773	3.5%
Drug Screen in the Following 183 Days				
00-11 Years	5	7.9%	5	7.4%
12-17 Years	50	4.0%	50	3.8%
18-24 Years	791	14.7%	832	14.4%
25-34 Years	3,181	19.7%	3,310	19.1%
35-44 Years	4,724	17.7%	4,914	16.9%
45-54 Years	6,363	14.2%	6,668	13.5%
55-64 Years	4,241	9.3%	4,432	8.8%

	New Users	Percentage of New Users with Drug Screen	New Episodes	Percentage of New Episodes with Drug Screen
Minimum Days Supplied = 84 Days				
All				
00-11 Years	2	N/A	2	N/A
12-17 Years	42	N/A	42	N/A
18-24 Years	683	N/A	693	N/A
25-34 Years	3,478	N/A	3,567	N/A
35-44 Years	6,095	N/A	6,225	N/A
45-54 Years	9,587	N/A	9,832	N/A
55-64 Years	7,999	N/A	8,183	N/A
Drug Screen in the Prior 30 Days				
00-11 Years	0	0.0%	0	0.0%
12-17 Years	3	7.1%	3	7.1%
18-24 Years	93	13.6%	93	13.4%
25-34 Years	549	15.8%	552	15.5%
35-44 Years	941	15.4%	952	15.3%
45-54 Years	1,190	12.4%	1,200	12.2%
55-64 Years	665	8.3%	668	8.2%
Drug Screen in the Following 183 Days				
00-11 Years	1	50.0%	1	50.0%
12-17 Years	7	16.7%	7	16.7%
18-24 Years	250	36.6%	251	36.2%
25-34 Years	1,225	35.2%	1,234	34.6%
35-44 Years	1,949	32.0%	1,976	31.7%
45-54 Years	2,546	26.6%	2,582	26.3%
55-64 Years	1,559	19.5%	1,572	19.2%

Appendix for Table 2: Summary of Extended-Release (ER) Oxycodone Use and Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Immediate Release (IR) Exclusion Requirement, Drug Screen Inclusion Requirement, and Age Group

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Eligible Members	Member-Years	New Users/1K Eligible	Days Supplied/ User	Dispensings/ User	Days Supplied/D ispending
183-day Incidence Assessment Period/Enrollment Requirement (No IR opioid use exclusion requirement)											
<i>Minimum Days Supplied = 1 Day</i>											
All											
00-11 Years	161	167	194	3,106	7,181	13,243,588	23,653,228.8	0.01	19.29	1.20	16.01
12-17 Years	4,135	4,245	5,005	57,819	127,925	8,633,760	13,934,701.5	0.48	13.98	1.21	11.55
18-24 Years	10,746	11,108	19,497	354,549	842,017	10,899,562	15,582,429.6	0.99	32.99	1.81	18.18
25-34 Years	22,092	22,748	61,810	1,406,387	3,406,586	15,396,703	22,356,369.4	1.43	63.66	2.80	22.75
35-44 Years	35,819	37,175	107,470	2,550,382	6,105,856	14,963,425	25,374,172.4	2.39	71.20	3.00	23.73
45-54 Years	61,634	64,399	176,011	4,203,562	9,908,438	15,344,433	28,415,531.4	4.02	68.20	2.86	23.88
55-64 Years	67,331	70,739	161,162	3,712,626	8,539,760	11,561,026	22,931,653.4	5.82	55.14	2.39	23.04
Drug Screen in the Prior 30 Days											
00-11 Years	1	1	1	10	20	N/A	N/A	N/A	10.00	1.00	10.00
12-17 Years	27	27	46	857	1,871	N/A	N/A	N/A	31.74	1.70	18.63
18-24 Years	432	434	1,343	32,200	75,422	N/A	N/A	N/A	74.54	3.11	23.98
25-34 Years	1,312	1,323	7,115	182,546	441,273	N/A	N/A	N/A	139.14	5.42	25.66
35-44 Years	1,954	1,971	11,176	300,035	687,814	N/A	N/A	N/A	153.55	5.72	26.85
45-54 Years	2,618	2,649	15,644	422,495	989,875	N/A	N/A	N/A	161.38	5.98	27.01
55-64 Years	1,669	1,683	8,737	239,525	550,080	N/A	N/A	N/A	143.51	5.23	27.42
Drug Screen in the Following 183 Days											
00-11 Years	3	3	3	47	95	N/A	N/A	N/A	15.67	1.00	15.67
12-17 Years	84	84	171	3,343	7,113	N/A	N/A	N/A	39.80	2.04	19.55
18-24 Years	948	966	3,391	84,140	200,336	N/A	N/A	N/A	88.76	3.58	24.81
25-34 Years	2,997	3,050	15,430	399,474	962,983	N/A	N/A	N/A	133.29	5.15	25.89
35-44 Years	4,323	4,392	24,319	645,703	1,550,689	N/A	N/A	N/A	149.36	5.63	26.55
45-54 Years	5,924	6,049	33,462	898,566	2,140,522	N/A	N/A	N/A	151.68	5.65	26.85
55-64 Years	4,107	4,182	20,334	546,666	1,268,704	N/A	N/A	N/A	133.11	4.95	26.88

	New Users	New Episodes	Days Dispensings	Days Supplied	Amount Supplied	Eligible Members	Member-Years	New Users/1K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/D ispending
183-day Incidence Assessment Period/Enrollment Requirement (No IR opioid use exclusion requirement)											
<i>Minimum Days Supplied = 84 Days</i>											
All											
00-11 Years	1	1	7	89	222	12,453,964	21,897,180.8	0.00	89.00	7.00	12.71
12-17 Years	48	48	345	9,167	20,637	8,156,421	12,987,184.4	0.01	190.98	7.19	26.57
18-24 Years	772	779	7,012	190,432	470,123	10,086,769	14,157,003.2	0.08	246.67	9.08	27.16
25-34 Years	3,289	3,318	37,055	1,015,985	2,529,097	14,153,632	20,206,346.8	0.23	308.90	11.27	27.42
35-44 Years	5,643	5,692	67,442	1,890,250	4,634,125	14,039,232	23,480,003.1	0.40	334.97	11.95	28.03
45-54 Years	8,990	9,088	105,700	3,000,020	7,254,905	14,554,047	26,570,440.9	0.62	333.71	11.76	28.38
55-64 Years	7,768	7,839	81,711	2,336,567	5,551,284	11,019,779	21,498,488.1	0.70	300.79	10.52	28.60
Drug Screen in the Prior 30 Days											
00-11 Years	0	0	0	0	0	N/A	N/A	N/A	---	---	---
12-17 Years	3	3	20	521	1,117	N/A	N/A	N/A	173.67	6.67	26.05
18-24 Years	102	102	860	23,397	56,038	N/A	N/A	N/A	229.38	8.43	27.21
25-34 Years	478	479	5,853	156,473	384,419	N/A	N/A	N/A	327.35	12.24	26.73
35-44 Years	800	804	9,432	262,579	605,397	N/A	N/A	N/A	328.22	11.79	27.84
45-54 Years	1,028	1,035	13,360	371,294	877,214	N/A	N/A	N/A	361.18	13.00	27.79
55-64 Years	606	607	7,217	205,725	477,824	N/A	N/A	N/A	339.48	11.91	28.51
Drug Screen in the Following 183 Days											
00-11 Years	0	0	0	0	0	N/A	N/A	N/A	---	---	---
12-17 Years	7	7	70	1,839	3,798	N/A	N/A	N/A	262.71	10.00	26.27
18-24 Years	271	273	2,334	64,951	155,241	N/A	N/A	N/A	239.67	8.61	27.83
25-34 Years	1,127	1,131	12,532	339,674	830,553	N/A	N/A	N/A	301.40	11.12	27.10
35-44 Years	1,679	1,687	20,351	561,810	1,361,374	N/A	N/A	N/A	334.61	12.12	27.61
45-54 Years	2,223	2,239	28,051	782,978	1,884,485	N/A	N/A	N/A	352.22	12.62	27.91
55-64 Years	1,409	1,414	16,474	464,674	1,086,943	N/A	N/A	N/A	329.79	11.69	28.21

	New Users	New Episodes	Days Dispensings	Days Supplied	Amount Supplied	Eligible Members	Member-Years	New Users/1K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/D ispending
90-day Incidence Assessment Period/Enrollment Requirement (No IR opioid use exclusion requirement)											
Minimum Days Supplied = 1 Day											
All											
00-11 Years	173	181	221	3,606	8,464	14,544,728	25,993,704.1	0.01	20.84	1.28	16.32
12-17 Years	4,447	4,638	5,509	64,183	142,689	9,218,630	14,903,088.0	0.48	14.43	1.24	11.65
18-24 Years	12,124	12,745	22,991	425,271	1,019,029	12,220,087	17,228,516.2	0.99	35.08	1.90	18.50
25-34 Years	25,803	27,294	76,467	1,760,041	4,282,828	17,150,102	24,891,372.4	1.50	68.21	2.96	23.02
35-44 Years	40,774	43,684	130,882	3,148,568	7,564,322	16,168,689	27,445,003.9	2.52	77.22	3.21	24.06
45-54 Years	69,102	74,886	213,691	5,187,301	12,341,777	16,303,740	30,337,538.1	4.24	75.07	3.09	24.27
55-64 Years	73,700	80,368	189,016	4,439,472	10,323,257	12,077,112	24,186,320.4	6.10	60.24	2.56	23.49
Drug Screen in the Prior 30 Days											
00-11 Years	1	1	1	10	20	N/A	N/A	N/A	10.00	1.00	10.00
12-17 Years	30	31	52	976	2,400	N/A	N/A	N/A	32.53	1.73	18.77
18-24 Years	514	523	1,613	38,410	89,947	N/A	N/A	N/A	74.73	3.14	23.81
25-34 Years	1,658	1,685	9,135	235,191	571,432	N/A	N/A	N/A	141.85	5.51	25.75
35-44 Years	2,450	2,497	14,504	389,353	905,263	N/A	N/A	N/A	158.92	5.92	26.84
45-54 Years	3,263	3,334	19,799	537,200	1,273,450	N/A	N/A	N/A	164.63	6.07	27.13
55-64 Years	2,010	2,053	10,614	291,128	670,925	N/A	N/A	N/A	144.84	5.28	27.43
Drug Screen in the Following 183 Days											
00-11 Years	5	5	15	339	920	N/A	N/A	N/A	67.80	3.00	22.60
12-17 Years	95	95	184	3,499	7,641	N/A	N/A	N/A	36.83	1.94	19.02
18-24 Years	1,139	1,186	4,229	102,973	247,343	N/A	N/A	N/A	90.41	3.71	24.35
25-34 Years	3,705	3,841	19,130	492,374	1,190,349	N/A	N/A	N/A	132.89	5.16	25.74
35-44 Years	5,397	5,599	31,029	824,474	1,979,531	N/A	N/A	N/A	152.77	5.75	26.57
45-54 Years	7,369	7,700	42,814	1,154,676	2,770,983	N/A	N/A	N/A	156.69	5.81	26.97
55-64 Years	4,997	5,202	25,242	681,715	1,599,794	N/A	N/A	N/A	136.42	5.05	27.01

	New Users	New Episodes	Days Dispensings	Days Supplied	Amount Supplied	Eligible Members	Member-Years	New Users/1K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/D ispending
90-day Incidence Assessment Period/Enrollment Requirement (No IR opioid use exclusion requirement)											
<i>Minimum Days Supplied = 84 Days</i>											
All											
00-11 Years	3	3	19	449	1,182	13,566,759	24,029,465.4	0.00	149.67	6.33	23.63
12-17 Years	58	59	404	10,795	24,230	8,667,521	13,876,982.2	0.01	186.12	6.97	26.72
18-24 Years	929	942	8,605	231,650	578,675	11,189,177	15,626,572.4	0.08	249.35	9.26	26.92
25-34 Years	4,149	4,250	46,892	1,283,487	3,205,134	15,655,694	22,465,948.5	0.27	309.35	11.30	27.37
35-44 Years	7,023	7,163	84,104	2,355,787	5,786,627	15,077,178	25,364,414.1	0.47	335.44	11.98	28.01
45-54 Years	11,139	11,410	132,764	3,766,472	9,186,418	15,393,166	28,346,820.5	0.72	338.13	11.92	28.37
55-64 Years	9,380	9,594	99,550	2,854,844	6,856,903	11,482,941	22,671,858.7	0.82	304.35	10.61	28.68
Drug Screen in the Prior 30 Days											
00-11 Years	0	0	0	0	0	N/A	N/A	N/A	---	---	---
12-17 Years	3	3	20	521	1,117	N/A	N/A	N/A	173.67	6.67	26.05
18-24 Years	118	118	1,018	27,457	65,578	N/A	N/A	N/A	232.69	8.63	26.97
25-34 Years	623	626	7,549	202,373	499,184	N/A	N/A	N/A	324.84	12.12	26.81
35-44 Years	1,024	1,035	12,304	342,225	800,860	N/A	N/A	N/A	334.20	12.02	27.81
45-54 Years	1,302	1,313	16,901	472,195	1,128,241	N/A	N/A	N/A	362.67	12.98	27.94
55-64 Years	733	738	8,770	249,517	581,106	N/A	N/A	N/A	340.41	11.96	28.45
Drug Screen in the Following 183 Days											
00-11 Years	1	1	9	270	780	N/A	N/A	N/A	270.00	9.00	30.00
12-17 Years	7	7	70	1,839	3,798	N/A	N/A	N/A	262.71	10.00	26.27
18-24 Years	324	326	2,905	78,732	190,243	N/A	N/A	N/A	243.00	8.97	27.10
25-34 Years	1,399	1,409	15,401	415,571	1,018,101	N/A	N/A	N/A	297.05	11.01	26.98
35-44 Years	2,155	2,182	25,974	716,968	1,735,042	N/A	N/A	N/A	332.70	12.05	27.60
45-54 Years	2,867	2,906	35,997	1,006,762	2,439,933	N/A	N/A	N/A	351.16	12.56	27.97
55-64 Years	1,767	1,782	20,495	579,048	1,370,751	N/A	N/A	N/A	327.70	11.60	28.25

	New Users	New Episodes	Days Dispensings	Days Supplied	Amount Supplied	Eligible Members	Member-Years	New Users/1K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/D ispending
183-day Incidence Assessment Period/Enrollment Requirement (IR opioid use exclusion requirement)											
Minimum Days Supplied = 1 Day											
All											
00-11 Years	102	105	114	1,604	3,656	13,240,788	23,504,722.7	0.01	15.73	1.12	14.07
12-17 Years	2,982	3,052	3,360	34,258	75,845	8,625,427	13,676,548.0	0.35	11.49	1.13	10.20
18-24 Years	6,020	6,160	8,569	125,373	299,544	10,865,595	15,015,994.8	0.55	20.83	1.42	14.63
25-34 Years	8,360	8,498	14,656	264,782	656,198	15,277,982	21,204,915.3	0.55	31.67	1.75	18.07
35-44 Years	12,480	12,777	21,383	391,701	951,557	14,775,692	23,839,890.9	0.84	31.39	1.71	18.32
45-54 Years	21,531	22,177	36,935	698,959	1,678,184	15,060,518	26,301,960.4	1.43	32.46	1.72	18.92
55-64 Years	25,550	26,436	39,696	713,339	1,654,587	11,303,534	20,929,471.0	2.26	27.92	1.55	17.97
Drug Screen in the Prior 30 Days											
00-11 Years	0	0	0	0	0	N/A	N/A	N/A	---	---	---
12-17 Years	15	15	17	218	457	N/A	N/A	N/A	14.53	1.13	12.82
18-24 Years	148	148	316	6,608	15,595	N/A	N/A	N/A	44.65	2.14	20.91
25-34 Years	175	175	961	22,167	61,978	N/A	N/A	N/A	126.67	5.49	23.07
35-44 Years	209	209	733	18,507	41,034	N/A	N/A	N/A	88.55	3.51	25.25
45-54 Years	314	315	1,514	38,985	98,861	N/A	N/A	N/A	124.16	4.82	25.75
55-64 Years	199	201	679	17,246	39,468	N/A	N/A	N/A	86.66	3.41	25.40
Drug Screen in the Following 183 Days											
00-11 Years	0	0	0	0	0	N/A	N/A	N/A	---	---	---
12-17 Years	39	39	45	475	1,071	N/A	N/A	N/A	12.18	1.15	10.56
18-24 Years	286	291	885	20,740	53,579	N/A	N/A	N/A	72.52	3.09	23.44
25-34 Years	399	400	2,057	49,859	134,296	N/A	N/A	N/A	124.96	5.16	24.24
35-44 Years	496	499	2,147	54,649	138,658	N/A	N/A	N/A	110.18	4.33	25.45
45-54 Years	739	747	3,430	90,162	224,232	N/A	N/A	N/A	122.01	4.64	26.29
55-64 Years	569	572	2,051	52,657	132,618	N/A	N/A	N/A	92.54	3.60	25.67

	New Users	New Episodes	Days Dispensings	Days Supplied	Amount Supplied	Eligible Members	Member-Years	New Users/1K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/D ispending
183-day Incidence Assessment Period/Enrollment Requirement (IR opioid use exclusion requirement)											
<i>Minimum Days Supplied = 84 Days</i>											
All											
00-11 Years	0	0	0	0	0	12,450,682	21,759,367.8	0.00	---	---	---
12-17 Years	13	13	82	2,310	5,721	8,147,729	12,746,038.4	0.00	177.69	6.31	28.17
18-24 Years	200	201	1,643	44,470	115,412	10,051,655	13,643,135.2	0.02	222.35	8.22	27.07
25-34 Years	513	515	5,178	140,785	372,121	14,038,982	19,173,236.2	0.04	274.43	10.09	27.19
35-44 Years	673	677	7,216	203,908	528,147	13,857,874	22,072,723.0	0.05	302.98	10.72	28.26
45-54 Years	1,103	1,111	12,245	352,220	907,721	14,277,842	24,605,597.3	0.08	319.33	11.10	28.76
55-64 Years	987	992	9,919	286,331	729,380	10,767,494	19,628,940.5	0.09	290.10	10.05	28.87
Drug Screen in the Prior 30 Days											
00-11 Years	0	0	0	0	0	N/A	N/A	N/A	---	---	---
12-17 Years	0	0	0	0	0	N/A	N/A	N/A	---	---	---
18-24 Years	23	23	138	3,822	9,335	N/A	N/A	N/A	166.17	6.00	27.70
25-34 Years	50	50	769	18,649	53,706	N/A	N/A	N/A	372.98	15.38	24.25
35-44 Years	54	54	507	14,224	31,642	N/A	N/A	N/A	263.41	9.39	28.06
45-54 Years	82	83	1,194	32,640	84,490	N/A	N/A	N/A	398.05	14.56	27.34
55-64 Years	44	44	476	13,347	31,035	N/A	N/A	N/A	303.34	10.82	28.04
Drug Screen in the Following 183 Days											
00-11 Years	0	0	0	0	0	N/A	N/A	N/A	---	---	---
12-17 Years	0	0	0	0	0	N/A	N/A	N/A	---	---	---
18-24 Years	64	65	536	15,189	39,234	N/A	N/A	N/A	237.33	8.38	28.34
25-34 Years	129	129	1,658	42,495	116,865	N/A	N/A	N/A	329.42	12.85	25.63
35-44 Years	145	145	1,661	45,359	117,429	N/A	N/A	N/A	312.82	11.46	27.31
45-54 Years	219	220	2,714	76,310	191,631	N/A	N/A	N/A	348.45	12.39	28.12
55-64 Years	136	136	1,480	41,826	107,789	N/A	N/A	N/A	307.54	10.88	28.26

	New Users	New Episodes	Days Dispensings	Days Supplied	Amount Supplied	Eligible Members	Member-Years	New Users/1K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/D ispending
90-day Incidence Assessment Period/Enrollment Requirement (IR opioid use exclusion requirement)											
Minimum Days Supplied = 1 Day											
All											
00-11 Years	110	113	124	1,780	4,056	14,541,772	25,834,145.2	0.01	16.18	1.13	14.35
12-17 Years	3,207	3,327	3,671	37,449	83,749	9,210,267	14,628,838.1	0.35	11.68	1.14	10.20
18-24 Years	6,740	6,955	9,937	149,993	365,360	12,181,707	16,603,954.3	0.55	22.25	1.47	15.09
25-34 Years	9,675	9,988	17,813	332,109	832,721	17,017,553	23,608,549.8	0.57	34.33	1.84	18.64
35-44 Years	14,061	14,688	26,241	510,243	1,254,217	15,968,177	25,774,121.2	0.88	36.29	1.87	19.44
45-54 Years	24,153	25,507	45,793	920,410	2,253,298	16,009,761	28,067,114.3	1.51	38.11	1.90	20.10
55-64 Years	28,128	29,905	47,060	897,328	2,122,939	11,817,178	22,060,313.3	2.38	31.90	1.67	19.07
Drug Screen in the Prior 30 Days											
00-11 Years	0	0	0	0	0	N/A	N/A	N/A	---	---	---
12-17 Years	16	16	18	248	637	N/A	N/A	N/A	15.50	1.13	13.78
18-24 Years	170	171	366	7,537	17,715	N/A	N/A	N/A	44.34	2.15	20.59
25-34 Years	235	235	1,344	32,172	90,114	N/A	N/A	N/A	136.90	5.72	23.94
35-44 Years	292	292	1,162	30,225	71,841	N/A	N/A	N/A	103.51	3.98	26.01
45-54 Years	414	416	2,032	53,769	139,303	N/A	N/A	N/A	129.88	4.91	26.46
55-64 Years	274	280	965	25,943	62,115	N/A	N/A	N/A	94.68	3.52	26.88
Drug Screen in the Following 183 Days											
00-11 Years	0	0	0	0	0	N/A	N/A	N/A	---	---	---
12-17 Years	45	45	51	552	1,356	N/A	N/A	N/A	12.27	1.13	10.82
18-24 Years	348	354	1,071	24,994	65,217	N/A	N/A	N/A	71.82	3.08	23.34
25-34 Years	524	531	2,588	62,537	168,520	N/A	N/A	N/A	119.35	4.94	24.16
35-44 Years	673	685	3,026	77,749	197,369	N/A	N/A	N/A	115.53	4.50	25.69
45-54 Years	1,006	1,032	5,193	138,454	349,083	N/A	N/A	N/A	137.63	5.16	26.66
55-64 Years	756	770	2,988	79,586	200,859	N/A	N/A	N/A	105.27	3.95	26.64

	New Users	New Episodes	Days Dispensings	Days Supplied	Amount Supplied	Eligible Members	Member-Years	New Users/1K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/D ispending
90-day Incidence Assessment Period/Enrollment Requirement (IR opioid use exclusion requirement)											
<i>Minimum Days Supplied = 84 Days</i>											
All											
00-11 Years	1	1	3	90	180	13,563,736	23,881,563.4	0.00	90.00	3.00	30.00
12-17 Years	16	17	103	2,748	6,959	8,659,136	13,621,005.1	0.00	171.75	6.44	26.68
18-24 Years	246	249	2,077	56,097	150,056	11,152,518	15,061,472.0	0.02	228.04	8.44	27.01
25-34 Years	671	683	6,698	183,342	489,460	15,534,135	21,318,476.4	0.04	273.24	9.98	27.37
35-44 Years	928	938	10,037	285,108	741,685	14,888,787	23,835,094.5	0.06	307.23	10.82	28.41
45-54 Years	1,552	1,578	17,600	506,562	1,320,949	15,112,120	26,238,188.6	0.10	326.39	11.34	28.78
55-64 Years	1,381	1,411	13,673	399,647	1,032,241	11,230,357	20,686,746.8	0.12	289.39	9.90	29.23
Drug Screen in the Prior 30 Days											
00-11 Years	0	0	0	0	0	N/A	N/A	N/A	---	---	---
12-17 Years	0	0	0	0	0	N/A	N/A	N/A	---	---	---
18-24 Years	25	25	155	4,114	10,028	N/A	N/A	N/A	164.56	6.20	26.54
25-34 Years	74	74	1,099	27,742	79,537	N/A	N/A	N/A	374.89	14.85	25.24
35-44 Years	83	83	851	24,200	58,290	N/A	N/A	N/A	291.57	10.25	28.44
45-54 Years	112	113	1,598	44,981	118,824	N/A	N/A	N/A	401.62	14.27	28.15
55-64 Years	68	70	689	20,261	49,249	N/A	N/A	N/A	297.96	10.13	29.41
Drug Screen in the Following 183 Days											
00-11 Years	0	0	0	0	0	N/A	N/A	N/A	---	---	---
12-17 Years	0	0	0	0	0	N/A	N/A	N/A	---	---	---
18-24 Years	74	75	636	17,881	47,011	N/A	N/A	N/A	241.64	8.59	28.11
25-34 Years	174	175	2,035	52,606	144,556	N/A	N/A	N/A	302.33	11.70	25.85
35-44 Years	206	206	2,353	64,626	166,834	N/A	N/A	N/A	313.72	11.42	27.47
45-54 Years	321	324	4,218	118,545	301,652	N/A	N/A	N/A	369.30	13.14	28.10
55-64 Years	208	210	2,251	64,901	166,550	N/A	N/A	N/A	312.02	10.82	28.83

Table 3: Percentage of New Extended-Release Oxycodone Users and Episodes with Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Evidence of Prior Immediate Release (IR) Opioid Use, and Sex

	New Users	Percentage of New Users with Drug Screen	New Episodes	Percentage of New Episodes with Drug Screen
All Incident Extended-Release Oxycodone Use				
183-day Incidence Assessment Period/Enrollment Requirement				
<i>Minimum Days Supplied = 1 Day</i>				
All				
Female	97,441	N/A	102,298	N/A
Male	103,226	N/A	108,267	N/A
Unknown	15	N/A	16	N/A
Drug Screen in the Prior 30 Days				
Female	3,794	3.9%	3,822	3.7%
Male	4,210	4.1%	4,266	3.9%
Unknown	0	0.0%	0	0.0%
Drug Screen in the Following 183 Days				
Female	8,942	9.2%	9,146	8.9%
Male	9,389	9.1%	9,578	8.8%
Unknown	2	13.3%	2	12.5%
<i>Minimum Days Supplied = 84 Days</i>				
All				
Female	12,289	N/A	12,421	N/A
Male	14,175	N/A	14,343	N/A
Unknown	1	N/A	1	N/A
Drug Screen in the Prior 30 Days				
Female	1,427	11.6%	1,434	11.5%
Male	1,587	11.2%	1,596	11.1%
Unknown	0	0.0%	0	0.0%
Drug Screen in the Following 183 Days				
Female	3,161	25.7%	3,179	25.6%
Male	3,549	25.0%	3,572	24.9%
Unknown	0	0.0%	0	0.0%

90-day Incidence Assessment Period/Enrollment Requirement	New Users	Percentage of New Users with Drug Screen	New Episodes	Percentage of New Episodes with Drug Screen
Minimum Days Supplied = 1 Day				
All				
Female	108,772	N/A	118,364	N/A
Male	115,497	N/A	125,415	N/A
Unknown	15	N/A	17	N/A
Drug Screen in the Prior 30 Days				
Female	4,713	4.3%	4,798	4.1%
Male	5,193	4.5%	5,325	4.2%
Unknown	1	6.7%	1	5.9%
Drug Screen in the Following 183 Days				
Female	11,025	10.1%	11,528	9.7%
Male	11,574	10.0%	12,097	9.6%
Unknown	2	13.3%	3	17.6%
Minimum Days Supplied = 84 Days				
All				
Female	15,191	N/A	15,566	N/A
Male	17,374	N/A	17,854	N/A
Unknown	1	N/A	1	N/A
Drug Screen in the Prior 30 Days				
Female	1,801	11.9%	1,818	11.7%
Male	1,997	11.5%	2,015	11.3%
Unknown	0	0.0%	0	0.0%
Drug Screen in the Following 183 Days				
Female	4,012	26.4%	4,062	26.1%
Male	4,493	25.9%	4,551	25.5%
Unknown	0	0.0%	0	0.0%

	New Users	Percentage of New Users with Drug Screen	New Episodes	Percentage of New Episodes with Drug Screen
Incident Extended-Release Oxycodone Use with an IR Opioid Prescription in the Prior 60 Days				
183-day Incidence Assessment Period/Enrollment Requirement				
<i>Minimum Days Supplied = 1 Day</i>				
All				
Female	61,604	N/A	65,347	N/A
Male	62,314	N/A	66,019	N/A
Unknown	9	N/A	10	N/A
Drug Screen in the Prior 30 Days	0		0	
Female	3,387	5.5%	3,415	5.2%
Male	3,558	5.7%	3,610	5.5%
Unknown	0	0.0%	0	0.0%
Drug Screen in the Following 183 Days	0		0	
Female	7,922	12.9%	8,119	12.4%
Male	7,881	12.6%	8,057	12.2%
Unknown	2	22.2%	2	20.0%
<i>Minimum Days Supplied = 84 Days</i>				
All				
Female	10,933	N/A	11,055	N/A
Male	12,046	N/A	12,200	N/A
Unknown	1	N/A	1	N/A
Drug Screen in the Prior 30 Days	0		0	
Female	1,340	12.3%	1,347	12.2%
Male	1,421	11.8%	1,429	11.7%
Unknown	0	0.0%	0	0.0%
Drug Screen in the Following 183 Days				
Female	2,911	26.6%	2,929	26.5%
Male	3,106	25.8%	3,127	25.6%
Unknown	0	0.0%	0	0.0%

90-day Incidence Assessment Period/Enrollment Requirement	New Users	Percentage of New Users with Drug Screen	New Episodes	Percentage of New Episodes with Drug Screen
<i>Minimum Days Supplied = 1 Day</i>				
All				
Female	68,888	N/A	76,293	N/A
Male	69,717	N/A	77,009	N/A
Unknown	9	N/A	11	N/A
Drug Screen in the Prior 30 Days				
Female	4,165	6.0%	4,245	5.6%
Male	4,342	6.2%	4,468	5.8%
Unknown	1	11.1%	1	9.1%
Drug Screen in the Following 183 Days				
Female	9,635	14.0%	10,107	13.2%
Male	9,617	13.8%	10,101	13.1%
Unknown	2	22.2%	3	27.3%
<i>Minimum Days Supplied = 84 Days</i>				
All				
Female	13,281	N/A	13,613	N/A
Male	14,498	N/A	14,930	N/A
Unknown	1	N/A	1	N/A
Drug Screen in the Prior 30 Days				
Female	1,667	12.6%	1,682	12.4%
Male	1,769	12.2%	1,786	12.0%
Unknown	0	0.0%	0	0.0%
Drug Screen in the Following 183 Days				
Female	3,632	27.3%	3,680	27.0%
Male	3,890	26.8%	3,943	26.4%
Unknown	0	0.0%	0	0.0%

Appendix for Table 3: Summary of Extended-Release (ER) Oxycodone Use and Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Immediate Release (IR) Exclusion Requirement, Drug Screen Inclusion Requirement, and Sex

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Eligible Members	Member-Years	New Users/1K Eligible	Days Supplied/ User	Dispensings/ User	Days Supplied/D ispending
183-day Incidence Assessment Period/Enrollment Requirement (No IR opioid use exclusion requirement)											
<i>Minimum Days Supplied = 1 Day</i>											
All											
Female	97,441	102,298	249,773	5,758,648	13,416,140	37,699,781	77,376,916.9	2.58	59.10	2.56	23.06
Male	103,226	108,267	281,353	6,529,367	15,520,780	37,012,034	74,865,524.8	2.79	63.25	2.73	23.21
Unknown	15	16	23	416	844	3,166	5,644.9	4.74	27.73	1.53	18.09
Drug Screen in the Prior 30 Days											
Female	3,794	3,822	20,588	553,911	1,270,230	N/A	N/A	N/A	146.00	5.43	26.90
Male	4,210	4,266	23,474	623,757	1,476,126	N/A	N/A	N/A	148.16	5.58	26.57
Unknown	0	0	0	0	0	N/A	N/A	N/A	---	---	---
Drug Screen in the Following 183 Days											
Female	8,942	9,146	45,019	1,201,015	2,808,775	N/A	N/A	N/A	134.31	5.03	26.68
Male	9,389	9,578	52,089	1,376,904	3,321,627	N/A	N/A	N/A	146.65	5.55	26.43
Unknown	2	2	2	20	40	N/A	N/A	N/A	10.00	1.00	10.00
<i>Minimum Days Supplied = 84 Days</i>											
All											
Female	12,289	12,421	136,982	3,877,976	9,281,757	35,538,362	71,583,038.0	0.35	315.56	11.15	28.31
Male	14,175	14,343	162,285	4,564,384	11,178,307	34,799,609	69,208,490.4	0.41	322.00	11.45	28.13
Unknown	1	1	5	150	330	2,896	5,118.9	0.35	150.00	5.00	30.00
Drug Screen in the Prior 30 Days											
Female	1,427	1,434	17,192	479,534	1,108,208	N/A	N/A	N/A	336.04	12.05	27.89
Male	1,587	1,596	19,550	540,455	1,293,801	N/A	N/A	N/A	340.55	12.32	27.64
Unknown	0	0	0	0	0	N/A	N/A	N/A	---	---	---
Drug Screen in the Following 183 Days											
Female	3,161	3,179	36,567	1,023,408	2,415,755	N/A	N/A	N/A	323.76	11.57	27.99
Male	3,549	3,572	43,245	1,192,518	2,906,639	N/A	N/A	N/A	336.02	12.19	27.58
Unknown	0	0	0	0	0	N/A	N/A	N/A	---	---	---

	New Users	New Episodes	Days Dispensings	Days Supplied	Amount Supplied	Eligible Members	Member-Years	New Users/1K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/D ispending
90-day Incidence Assessment Period/Enrollment Requirement (No IR opioid use exclusion requirement)											
Minimum Days Supplied = 1 Day											
All											
Female	108,772	118,364	300,705	7,060,476	16,585,132	40,829,661	83,762,867.7	2.66	64.91	2.76	23.48
Male	115,497	125,415	338,047	7,967,490	19,096,269	40,227,598	81,216,484.0	2.87	68.98	2.93	23.57
Unknown	15	17	25	476	964	3,649	6,191.5	4.11	31.73	1.67	19.04
Drug Screen in the Prior 30 Days											
Female	4,713	4,798	26,097	701,665	1,614,501	N/A	N/A	N/A	148.88	5.54	26.89
Male	5,193	5,325	29,619	790,543	1,898,818	N/A	N/A	N/A	152.23	5.70	26.69
Unknown	1	1	2	60	120	N/A	N/A	N/A	60.00	2.00	30.00
Drug Screen in the Following 183 Days											
Female	11,025	11,528	56,753	1,511,972	3,551,221	N/A	N/A	N/A	137.14	5.15	26.64
Male	11,574	12,097	65,886	1,747,998	4,245,180	N/A	N/A	N/A	151.03	5.69	26.53
Unknown	2	3	4	80	160	N/A	N/A	N/A	40.00	2.00	20.00
Minimum Days Supplied = 84 Days											
All											
Female	15,191	15,566	171,239	4,848,436	11,688,240	38,214,800	77,400,774.3	0.40	319.17	11.27	28.31
Male	17,374	17,854	201,094	5,654,898	13,950,598	37,516,593	74,975,699.6	0.46	325.48	11.57	28.12
Unknown	1	1	5	150	330	3,236	5,587.8	0.31	150.00	5.00	30.00
Drug Screen in the Prior 30 Days											
Female	1,801	1,818	21,828	608,069	1,408,631	N/A	N/A	N/A	337.63	12.12	27.86
Male	1,997	2,015	24,734	686,219	1,667,455	N/A	N/A	N/A	343.62	12.39	27.74
Unknown	0	0	0	0	0	N/A	N/A	N/A	---	---	---
Drug Screen in the Following 183 Days											
Female	4,012	4,062	46,147	1,286,639	3,047,527	N/A	N/A	N/A	320.70	11.50	27.88
Male	4,493	4,551	54,704	1,512,551	3,711,122	N/A	N/A	N/A	336.65	12.18	27.65
Unknown	0	0	0	0	0	N/A	N/A	N/A	---	---	---

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Eligible Members	Member-Years	New Users/1K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/D ispending
183-day Incidence Assessment Period/Enrollment Requirement (IR opioid use exclusion requirement)											
Minimum Days Supplied = 1 Day											
All											
Female	35,837	36,951	54,776	946,048	2,203,088	37,316,324	72,867,309.1	0.96	26.40	1.53	17.27
Male	40,912	42,248	69,930	1,283,887	3,116,292	36,717,959	71,600,854.4	1.11	31.38	1.71	18.36
Unknown	6	6	7	81	192	3,141	5,339.4	1.91	13.50	1.17	11.57
Drug Screen in the Prior 30 Days											
Female	407	407	1,446	35,905	85,002	N/A	N/A	N/A	88.22	3.55	24.83
Male	652	656	2,774	67,826	172,391	N/A	N/A	N/A	104.03	4.25	24.45
Unknown	0	0	0	0	0	N/A	N/A	N/A	---	---	---
Drug Screen in the Following 183 Days											
Female	1,020	1,027	3,869	98,509	247,053	N/A	N/A	N/A	96.58	3.79	25.46
Male	1,508	1,521	6,746	170,033	437,401	N/A	N/A	N/A	112.75	4.47	25.21
Unknown	0	0	0	0	0	N/A	N/A	N/A	---	---	---
Minimum Days Supplied = 84 Days											
All											
Female	1,356	1,366	13,594	390,465	976,391	35,156,538	67,426,966.8	0.04	287.95	10.03	28.72
Male	2,129	2,143	22,689	639,559	1,682,110	34,509,611	66,197,235.1	0.06	300.40	10.66	28.19
Unknown	0	0	0	0	0	2,875	4,836.5	0.00	---	---	---
Drug Screen in the Prior 30 Days											
Female	87	87	1,017	28,213	67,763	N/A	N/A	N/A	324.29	11.69	27.74
Male	166	167	2,067	54,469	142,445	N/A	N/A	N/A	328.13	12.45	26.35
Unknown	0	0	0	0	0	N/A	N/A	N/A	---	---	---
Drug Screen in the Following 183 Days											
Female	250	250	2,832	79,412	202,999	N/A	N/A	N/A	317.65	11.33	28.04
Male	443	445	5,217	141,767	369,949	N/A	N/A	N/A	320.02	11.78	27.17
Unknown	0	0	0	0	0	N/A	N/A	N/A	---	---	---

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Eligible Members	Member-Years	New Users/1K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/D ispending
90-day Incidence Assessment Period/Enrollment Requirement (IR opioid use exclusion requirement)											
Minimum Days Supplied = 1 Day											
All											
Female	39,884	42,071	66,116	1,218,673	2,901,742	40,432,973	78,891,349.8	0.99	30.56	1.66	18.43
Male	45,780	48,406	84,516	1,630,558	4,014,406	39,919,784	77,679,825.8	1.15	35.62	1.85	19.29
Unknown	6	6	7	81	192	3,617	5,860.6	1.66	13.50	1.17	11.57
Drug Screen in the Prior 30 Days											
Female	548	553	2,153	56,027	139,125	N/A	N/A	N/A	102.24	3.93	26.02
Male	851	857	3,734	93,867	242,600	N/A	N/A	N/A	110.30	4.39	25.14
Unknown	0	0	0	0	0	N/A	N/A	N/A	---	---	---
Drug Screen in the Following 183 Days											
Female	1,390	1,421	5,725	148,913	376,970	N/A	N/A	N/A	107.13	4.12	26.01
Male	1,957	1,996	9,192	234,959	605,434	N/A	N/A	N/A	120.06	4.70	25.56
Unknown	0	0	0	0	0	N/A	N/A	N/A	---	---	---
Minimum Days Supplied = 84 Days											
All											
Female	1,910	1,953	19,529	565,085	1,441,987	37,830,962	72,917,473.1	0.05	295.86	10.22	28.94
Male	2,876	2,924	30,662	868,509	2,299,543	37,223,282	71,719,791.1	0.08	301.99	10.66	28.33
Unknown	0	0	0	0	0	3,215	5,282.6	0.00	---	---	---
Drug Screen in the Prior 30 Days											
Female	134	136	1,570	45,002	113,582	N/A	N/A	N/A	335.84	11.72	28.66
Male	228	229	2,822	76,296	202,346	N/A	N/A	N/A	334.63	12.38	27.04
Unknown	0	0	0	0	0	N/A	N/A	N/A	---	---	---
Drug Screen in the Following 183 Days											
Female	380	382	4,312	121,502	312,844	N/A	N/A	N/A	319.74	11.35	28.18
Male	603	608	7,181	197,057	513,759	N/A	N/A	N/A	326.79	11.91	27.44
Unknown	0	0	0	0	0	N/A	N/A	N/A	---	---	---

Table 4: Percentage of New Extended-Release Oxycodone Users and Episodes with Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Evidence of Prior Immediate Release (IR) Opioid Use, and Year

	New Users	Percentage of New Users with Drug Screen	New Episodes	Percentage of New Episodes with Drug Screen
All Incident Extended-Release Oxycodone Use				
183-day Incidence Assessment Period/Enrollment Requirement				
<i>Minimum Days Supplied = 1 Day</i>				
All				
2009	52,071	N/A	52,356	N/A
2010	47,423	N/A	47,698	N/A
2011	39,704	N/A	39,930	N/A
2012	36,468	N/A	36,668	N/A
2013	33,716	N/A	33,929	N/A
Drug Screen in the Prior 30 Days				
2009	1,533	2.9%	1,535	2.9%
2010	1,595	3.4%	1,595	3.3%
2011	1,394	3.5%	1,395	3.5%
2012	1,792	4.9%	1,794	4.9%
2013	1,767	5.2%	1,769	5.2%
Drug Screen in the Following 183 Days				
2009	3,914	7.5%	3,918	7.5%
2010	4,009	8.5%	4,013	8.4%
2011	3,314	8.3%	3,321	8.3%
2012	3,783	10.4%	3,788	10.3%
2013	3,681	10.9%	3,686	10.9%
<i>Minimum Days Supplied = 84 Days</i>				
All				
2009	7,675	N/A	7,675	N/A
2010	6,408	N/A	6,408	N/A
2011	4,476	N/A	4,477	N/A
2012	4,317	N/A	4,318	N/A
2013	3,887	N/A	3,887	N/A
Drug Screen in the Prior 30 Days				
2009	593	7.7%	593	7.7%
2010	637	9.9%	637	9.9%
2011	483	10.8%	483	10.8%
2012	652	15.1%	652	15.1%
2013	665	17.1%	665	17.1%
Drug Screen in the Following 183 Days				
2009	1,491	19.4%	1,491	19.4%
2010	1,509	23.5%	1,509	23.5%
2011	1,060	23.7%	1,060	23.7%
2012	1,358	31.5%	1,358	31.4%
2013	1,333	34.3%	1,333	34.3%



90-day Incidence Assessment Period/Enrollment Requirement	New Users	Percentage of New Users with Drug Screen	New Episodes	Percentage of New Episodes with Drug Screen
Minimum Days Supplied = 1 Day				
All				
2009	59,800	N/A	61,248	N/A
2010	54,068	N/A	55,351	N/A
2011	45,055	N/A	46,109	N/A
2012	41,212	N/A	42,144	N/A
2013	38,084	N/A	38,944	N/A
Drug Screen in the Prior 30 Days				
2009	1,934	3.2%	1,946	3.2%
2010	2,008	3.7%	2,020	3.6%
2011	1,751	3.9%	1,760	3.8%
2012	2,192	5.3%	2,201	5.2%
2013	2,184	5.7%	2,197	5.6%
Drug Screen in the Following 183 Days				
2009	4,981	8.3%	5,029	8.2%
2010	5,039	9.3%	5,096	9.2%
2011	4,135	9.2%	4,184	9.1%
2012	4,690	11.4%	4,744	11.3%
2013	4,525	11.9%	4,575	11.7%
Minimum Days Supplied = 84 Days				
All				
2009	9,586	N/A	9,610	N/A
2010	8,000	N/A	8,015	N/A
2011	5,561	N/A	5,574	N/A
2012	5,411	N/A	5,420	N/A
2013	4,796	N/A	4,802	N/A
Drug Screen in the Prior 30 Days				
2009	752	7.8%	752	7.8%
2010	795	9.9%	795	9.9%
2011	638	11.5%	638	11.4%
2012	817	15.1%	817	15.1%
2013	831	17.3%	831	17.3%
Drug Screen in the Following 183 Days				
2009	1,903	19.9%	1,904	19.8%
2010	1,920	24.0%	1,920	24.0%
2011	1,359	24.4%	1,361	24.4%
2012	1,738	32.1%	1,740	32.1%
2013	1,688	35.2%	1,688	35.2%

	New Users	Percentage of New Users with Drug Screen	New Episodes	Percentage of New Episodes with Drug Screen
Incident Extended-Release Oxycodone Use with an IR Opioid Prescription in the Prior 60 Days				
183-day Incidence Assessment Period/Enrollment Requirement				
All				
2009	33,099	N/A	33,305	N/A
2010	29,918	N/A	30,119	N/A
2011	24,643	N/A	24,795	N/A
2012	22,276	N/A	22,401	N/A
2013	20,614	N/A	20,756	N/A
Drug Screen in the Prior 30 Days				
2009	1,297	3.9%	1,299	3.9%
2010	1,353	4.5%	1,353	4.5%
2011	1,214	4.9%	1,215	4.9%
2012	1,564	7.0%	1,565	7.0%
2013	1,591	7.7%	1,593	7.7%
Drug Screen in the Following 183 Days				
2009	3,276	9.9%	3,279	9.8%
2010	3,450	11.5%	3,454	11.5%
2011	2,901	11.8%	2,908	11.7%
2012	3,300	14.8%	3,305	14.8%
2013	3,227	15.7%	3,232	15.6%
Minimum Days Supplied = 84 Days				
All				
2009	6,394	N/A	6,394	N/A
2010	5,529	N/A	5,529	N/A
2011	3,956	N/A	3,956	N/A
2012	3,857	N/A	3,858	N/A
2013	3,519	N/A	3,519	N/A
Drug Screen in the Prior 30 Days				
2009	533	8.3%	533	8.3%
2010	580	10.5%	580	10.5%
2011	442	11.2%	442	11.2%
2012	599	15.5%	599	15.5%
2013	622	17.7%	622	17.7%
Drug Screen in the Following 183 Days				
2009	1,278	20.0%	1,278	20.0%
2010	1,337	24.2%	1,337	24.2%
2011	963	24.3%	963	24.3%
2012	1,244	32.3%	1,244	32.2%
2013	1,234	35.1%	1,234	35.1%

90-day Incidence Assessment Period/Enrollment Requirement	New Users	Percentage of New Users with Drug Screen	New Episodes	Percentage of New Episodes with Drug Screen
Minimum Days Supplied = 1 Day				
All				
2009	38,096	N/A	39,151	N/A
2010	34,244	N/A	35,196	N/A
2011	28,113	N/A	28,887	N/A
2012	25,354	N/A	26,025	N/A
2013	23,433	N/A	24,054	N/A
Drug Screen in the Prior 30 Days				
2009	1,615	4.2%	1,626	4.2%
2010	1,688	4.9%	1,700	4.8%
2011	1,522	5.4%	1,530	5.3%
2012	1,893	7.5%	1,901	7.3%
2013	1,944	8.3%	1,957	8.1%
Drug Screen in the Following 183 Days				
2009	4,131	10.8%	4,172	10.7%
2010	4,284	12.5%	4,337	12.3%
2011	3,576	12.7%	3,623	12.5%
2012	4,045	16.0%	4,097	15.7%
2013	3,933	16.8%	3,982	16.6%
Minimum Days Supplied = 84 Days				
All				
2009	7,843	N/A	7,860	N/A
2010	6,780	N/A	6,791	N/A
2011	4,858	N/A	4,870	N/A
2012	4,744	N/A	4,752	N/A
2013	4,265	N/A	4,271	N/A
Drug Screen in the Prior 30 Days				
2009	663	8.5%	663	8.4%
2010	713	10.5%	713	10.5%
2011	580	11.9%	580	11.9%
2012	742	15.6%	742	15.6%
2013	770	18.1%	770	18.0%
Drug Screen in the Following 183 Days				
2009	1,604	20.5%	1,605	20.4%
2010	1,679	24.8%	1,679	24.7%
2011	1,223	25.2%	1,225	25.2%
2012	1,567	33.0%	1,569	33.0%
2013	1,545	36.2%	1,545	36.2%

Appendix for Table 4: Summary of Extended-Release (ER) Oxycodone Use and Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Immediate Release (IR) Exclusion Requirement, Drug Screen Inclusion Requirement, and Year

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Eligible Members	Member-Years	New Users/1K Eligible	Days Supplied/ User	Dispensings/ User	Days Supplied/Dispensing
183-day Incidence Assessment Period/Enrollment Requirement (No IR opioid use exclusion requirement)											
<i>Minimum Days Supplied = 1 Day</i>											
All											
2009	52,071	52,356	153,595	3,724,013	9,290,861	42,571,154	32,832,308.7	1.22	71.52	2.95	24.25
2010	47,423	47,698	126,644	2,989,208	7,170,449	40,362,449	31,321,712.0	1.17	63.03	2.67	23.60
2011	39,704	39,930	94,390	2,140,289	4,923,153	38,903,987	30,402,556.4	1.02	53.91	2.38	22.67
2012	36,468	36,668	86,205	1,933,715	4,344,552	37,647,762	29,523,402.3	0.97	53.02	2.36	22.43
2013	33,716	33,929	70,315	1,501,206	3,208,748	36,292,301	28,168,107.2	0.93	44.53	2.09	21.35
Drug Screen in the Prior 30 Days											
2009	1,533	1,535	9,855	261,037	658,850	N/A	N/A	N/A	170.28	6.43	26.49
2010	1,595	1,595	9,582	257,809	629,211	N/A	N/A	N/A	161.64	6.01	26.91
2011	1,394	1,395	7,347	198,980	458,894	N/A	N/A	N/A	142.74	5.27	27.08
2012	1,792	1,794	9,567	257,436	568,139	N/A	N/A	N/A	143.66	5.34	26.91
2013	1,767	1,769	7,711	202,406	431,262	N/A	N/A	N/A	114.55	4.36	26.25
Drug Screen in the Following 183 Days											
2009	3,914	3,918	23,372	618,520	1,614,895	N/A	N/A	N/A	158.03	5.97	26.46
2010	4,009	4,013	23,127	623,864	1,529,545	N/A	N/A	N/A	155.62	5.77	26.98
2011	3,314	3,321	16,194	430,640	999,161	N/A	N/A	N/A	129.95	4.89	26.59
2012	3,783	3,788	18,796	498,967	1,120,210	N/A	N/A	N/A	131.90	4.97	26.55
2013	3,681	3,686	15,621	405,948	866,631	N/A	N/A	N/A	110.28	4.24	25.99
<i>Minimum Days Supplied = 84 Days</i>											
All											
2009	7,675	7,675	96,536	2,738,827	7,059,269	40,259,262	30,341,666.1	0.19	356.85	12.58	28.37
2010	6,408	6,408	74,288	2,103,120	5,192,251	38,358,529	29,043,530.3	0.17	328.20	11.59	28.31
2011	4,476	4,477	49,976	1,414,577	3,327,151	37,073,817	28,264,241.2	0.12	316.04	11.17	28.31
2012	4,317	4,318	45,732	1,282,863	2,930,331	35,845,880	27,364,289.2	0.12	297.17	10.59	28.05
2013	3,887	3,887	32,740	903,123	1,951,392	34,495,970	25,782,920.5	0.11	232.34	8.42	27.58
Drug Screen in the Prior 30 Days											
2009	593	593	8,461	231,891	591,666	N/A	N/A	N/A	391.05	14.27	27.41
2010	637	637	8,184	228,069	562,217	N/A	N/A	N/A	358.04	12.85	27.87
2011	483	483	6,057	170,621	396,903	N/A	N/A	N/A	353.25	12.54	28.17
2012	652	652	7,933	221,688	491,323	N/A	N/A	N/A	340.01	12.17	27.95
2013	665	665	6,107	167,720	359,899	N/A	N/A	N/A	252.21	9.18	27.46
Drug Screen in the Following 183 Days											

2009	1,491	1,491	19,764	542,979	1,436,376	N/A	N/A	N/A	364.17	13.26	27.47
2010	1,509	1,509	19,506	546,877	1,356,701	N/A	N/A	N/A	362.41	12.93	28.04
2011	1,060	1,060	12,955	362,827	847,243	N/A	N/A	N/A	342.29	12.22	28.01
2012	1,358	1,358	15,387	427,700	963,869	N/A	N/A	N/A	314.95	11.33	27.80
2013	1,333	1,333	12,200	335,543	718,205	N/A	N/A	N/A	251.72	9.15	27.50

	New Users	New Episodes	Days Dispensings	Days Supplied	Amount Supplied	Eligible Members	Member-Years	New Users/1K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/D ispending
90-day Incidence Assessment Period/Enrollment Requirement (No IR opioid use exclusion requirement)											
Minimum Days Supplied = 1 Day											
All											
2009	59,800	61,248	185,804	4,562,460	11,457,010	45,860,980	35,655,184.5	1.30	76.30	3.11	24.56
2010	54,068	55,351	152,247	3,649,640	8,815,300	43,604,978	33,918,222.0	1.24	67.50	2.82	23.97
2011	45,055	46,109	113,865	2,630,659	6,118,274	42,083,174	32,920,405.0	1.07	58.39	2.53	23.10
2012	41,212	42,144	103,538	2,370,439	5,382,046	40,747,245	31,920,844.5	1.01	57.52	2.51	22.89
2013	38,084	38,944	83,323	1,815,244	3,909,735	39,271,856	30,570,887.2	0.97	47.66	2.19	21.79
Drug Screen in the Prior 30 Days											
2009	1,934	1,946	12,451	332,572	837,089	N/A	N/A	N/A	171.96	6.44	26.71
2010	2,008	2,020	12,114	326,009	809,689	N/A	N/A	N/A	162.36	6.03	26.91
2011	1,751	1,760	9,552	258,958	603,877	N/A	N/A	N/A	147.89	5.46	27.11
2012	2,192	2,201	11,959	322,537	722,557	N/A	N/A	N/A	147.14	5.46	26.97
2013	2,184	2,197	9,642	252,192	540,226	N/A	N/A	N/A	115.47	4.41	26.16
Drug Screen in the Following 183 Days											
2009	4,981	5,029	29,162	772,832	2,002,853	N/A	N/A	N/A	155.16	5.85	26.50
2010	5,039	5,096	29,042	780,985	1,930,905	N/A	N/A	N/A	154.99	5.76	26.89
2011	4,135	4,184	20,808	554,566	1,302,305	N/A	N/A	N/A	134.12	5.03	26.65
2012	4,690	4,744	24,045	641,704	1,460,912	N/A	N/A	N/A	136.82	5.13	26.69
2013	4,525	4,575	19,586	509,963	1,099,585	N/A	N/A	N/A	112.70	4.33	26.04
Minimum Days Supplied = 84 Days											
All											
2009	9,586	9,610	119,648	3,393,499	8,786,340	43,213,237	32,909,563.8	0.22	354.01	12.48	28.36
2010	8,000	8,015	91,929	2,603,217	6,460,387	41,280,376	31,416,803.0	0.19	325.40	11.49	28.32
2011	5,561	5,574	62,906	1,778,001	4,231,509	39,944,631	30,564,149.8	0.14	319.73	11.31	28.26
2012	5,411	5,420	57,365	1,610,349	3,721,108	38,580,301	29,543,801.0	0.14	297.61	10.60	28.07
2013	4,796	4,802	40,490	1,118,418	2,439,824	37,181,908	27,947,744.2	0.13	233.20	8.44	27.62
Drug Screen in the Prior 30 Days											
2009	752	752	10,681	295,113	749,386	N/A	N/A	N/A	392.44	14.20	27.63
2010	795	795	10,310	287,288	721,300	N/A	N/A	N/A	361.37	12.97	27.86
2011	638	638	7,949	223,962	526,959	N/A	N/A	N/A	351.04	12.46	28.17
2012	817	817	9,973	278,858	627,594	N/A	N/A	N/A	341.32	12.21	27.96
2013	831	831	7,649	209,067	450,847	N/A	N/A	N/A	251.58	9.20	27.33
Drug Screen in the Following 183 Days											
2009	1,903	1,904	24,515	673,998	1,767,666	N/A	N/A	N/A	354.18	12.88	27.49
2010	1,920	1,920	24,378	681,591	1,705,275	N/A	N/A	N/A	355.00	12.70	27.96
2011	1,359	1,361	16,740	468,733	1,109,007	N/A	N/A	N/A	344.91	12.32	28.00

2012	1,738	1,740	19,806	551,369	1,260,903	N/A	N/A	N/A	317.24	11.40	27.84
2013	1,688	1,688	15,412	423,499	915,798	N/A	N/A	N/A	250.89	9.13	27.48

	New Users	New Episodes	Days Dispensings	Days Supplied	Amount Supplied	Eligible Members	Member-Years	New Users/1K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/D ispending
183-day Incidence Assessment Period/Enrollment Requirement (IR opioid use exclusion requirement)											
Minimum Days Supplied = 1 Day											
All											
2009	18,972	19,051	35,803	723,901	1,817,971	42,088,338	31,132,674.4	0.45	38.16	1.89	20.22
2010	17,505	17,579	28,566	533,294	1,310,059	39,881,465	29,691,519.0	0.44	30.47	1.63	18.67
2011	15,061	15,135	22,196	372,884	861,984	38,423,577	28,831,535.3	0.39	24.76	1.47	16.80
2012	14,192	14,267	20,327	329,419	746,765	37,176,119	28,021,140.2	0.38	23.21	1.43	16.21
2013	13,102	13,173	17,821	270,518	582,793	35,841,727	26,796,634.0	0.37	20.65	1.36	15.18
Drug Screen in the Prior 30 Days											
2009	236	236	1,272	30,419	85,921	N/A	N/A	N/A	128.89	5.39	23.91
2010	242	242	884	21,818	53,397	N/A	N/A	N/A	90.16	3.65	24.68
2011	180	180	628	16,123	38,751	N/A	N/A	N/A	89.57	3.49	25.67
2012	228	229	865	21,335	48,394	N/A	N/A	N/A	93.57	3.79	24.66
2013	176	176	571	14,036	30,931	N/A	N/A	N/A	79.75	3.24	24.58
Drug Screen in the Following 183 Days											
2009	638	639	3,425	88,103	247,759	N/A	N/A	N/A	138.09	5.37	25.72
2010	559	559	2,561	65,938	166,375	N/A	N/A	N/A	117.96	4.58	25.75
2011	413	413	1,618	41,008	100,141	N/A	N/A	N/A	99.29	3.92	25.34
2012	483	483	1,668	41,481	98,531	N/A	N/A	N/A	85.88	3.45	24.87
2013	454	454	1,343	32,012	71,648	N/A	N/A	N/A	70.51	2.96	23.84
Minimum Days Supplied = 84 Days											
All											
2009	1,281	1,281	14,807	421,930	1,127,421	39,785,649	28,772,413.9	0.03	329.38	11.56	28.50
2010	879	879	9,004	258,176	687,866	37,882,398	27,534,238.3	0.02	293.72	10.24	28.67
2011	520	521	5,210	147,537	364,238	36,598,031	26,807,375.7	0.01	283.73	10.02	28.32
2012	460	460	4,289	120,721	294,458	35,376,375	25,984,062.6	0.01	262.44	9.32	28.15
2013	368	368	2,973	81,660	184,519	34,048,883	24,530,947.9	0.01	221.90	8.08	27.47
Drug Screen in the Prior 30 Days											
2009	60	60	1,015	25,756	75,266	N/A	N/A	N/A	429.27	16.92	25.38
2010	57	57	635	17,535	43,399	N/A	N/A	N/A	307.63	11.14	27.61
2011	41	41	436	12,377	30,593	N/A	N/A	N/A	301.88	10.63	28.39
2012	53	53	619	16,666	37,955	N/A	N/A	N/A	314.45	11.68	26.92
2013	43	43	379	10,348	22,995	N/A	N/A	N/A	240.65	8.81	27.30
Drug Screen in the Following 183 Days											
2009	213	213	2,823	76,528	219,140	N/A	N/A	N/A	359.29	13.25	27.11
2010	172	172	2,013	55,688	142,443	N/A	N/A	N/A	323.77	11.70	27.66
2011	97	97	1,192	33,241	81,137	N/A	N/A	N/A	342.69	12.29	27.89

2012	114	114	1,172	32,442	77,861	N/A	N/A	N/A	284.58	10.28	27.68
2013	99	99	849	23,280	52,367	N/A	N/A	N/A	235.15	8.58	27.42

	New Users	New Episodes	Days Dispensings	Days Supplied	Amount Supplied	Eligible Members	Member-Years	New Users/1K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/D ispending
90-day Incidence Assessment Period/Enrollment Requirement (IR opioid use exclusion requirement)											
Minimum Days Supplied = 1 Day											
All											
2009	21,704	22,097	43,922	927,864	2,373,795	45,359,426	33,813,487.2	0.48	42.75	2.02	21.13
2010	19,824	20,155	34,721	683,820	1,704,154	43,103,737	32,159,530.8	0.46	34.49	1.75	19.69
2011	16,942	17,222	26,342	468,947	1,096,700	41,580,912	31,221,876.1	0.41	27.68	1.55	17.80
2012	15,858	16,119	24,559	428,555	997,880	40,250,540	30,297,967.4	0.39	27.02	1.55	17.45
2013	14,651	14,890	21,095	340,126	743,811	38,808,438	29,084,174.7	0.38	23.22	1.44	16.12
Drug Screen in the Prior 30 Days											
2009	319	320	1,708	42,355	118,040	N/A	N/A	N/A	132.77	5.35	24.80
2010	320	320	1,358	35,572	94,102	N/A	N/A	N/A	111.16	4.24	26.19
2011	229	230	829	21,326	52,446	N/A	N/A	N/A	93.13	3.62	25.72
2012	299	300	1,192	30,187	70,580	N/A	N/A	N/A	100.96	3.99	25.32
2013	240	240	800	20,454	46,558	N/A	N/A	N/A	85.23	3.33	25.57
Drug Screen in the Following 183 Days											
2009	850	857	4,630	120,502	331,260	N/A	N/A	N/A	141.77	5.45	26.03
2010	755	759	3,548	92,426	237,515	N/A	N/A	N/A	122.42	4.70	26.05
2011	559	561	2,309	59,192	148,555	N/A	N/A	N/A	105.89	4.13	25.64
2012	645	647	2,580	66,340	161,235	N/A	N/A	N/A	102.85	4.00	25.71
2013	592	593	1,850	45,412	103,840	N/A	N/A	N/A	76.71	3.13	24.55
Minimum Days Supplied = 84 Days											
All											
2009	1,743	1,750	19,789	566,960	1,537,195	42,724,405	31,212,022.4	0.04	325.28	11.35	28.65
2010	1,220	1,224	12,392	356,711	955,328	40,789,374	29,790,784.7	0.03	292.39	10.16	28.79
2011	703	704	7,072	203,669	506,372	39,451,890	28,991,681.7	0.02	289.71	10.06	28.80
2012	667	668	6,554	185,358	464,773	38,094,201	28,055,385.9	0.02	277.90	9.83	28.28
2013	531	531	4,384	120,896	277,863	36,725,100	26,592,672.0	0.01	227.68	8.26	27.58
Drug Screen in the Prior 30 Days											
2009	89	89	1,365	35,854	102,633	N/A	N/A	N/A	402.85	15.34	26.27
2010	82	82	1,021	29,501	79,464	N/A	N/A	N/A	359.77	12.45	28.89
2011	58	58	586	16,589	41,981	N/A	N/A	N/A	286.02	10.10	28.31
2012	75	75	879	24,043	56,527	N/A	N/A	N/A	320.57	11.72	27.35
2013	61	61	541	15,311	35,323	N/A	N/A	N/A	251.00	8.87	28.30
Drug Screen in the Following 183 Days											
2009	299	299	3,830	104,865	292,611	N/A	N/A	N/A	350.72	12.81	27.38
2010	241	241	2,780	77,623	202,493	N/A	N/A	N/A	322.09	11.54	27.92
2011	136	136	1,722	48,180	121,919	N/A	N/A	N/A	354.26	12.66	27.98

2012	171	171	1,940	53,937	131,818	N/A	N/A	N/A	315.42	11.35	27.80
2013	143	143	1,221	33,954	77,763	N/A	N/A	N/A	237.44	8.54	27.81

Appendix A: List of Drugs used for Exposures in this Request

Generic Name	Brand Name	Route	Form	Strength	Unit
Extended-Release (ER) Oxycodone					
OXYCODONE HCL	OxyContin	oral	tablet extended release 12 hr	10	mg
OXYCODONE HCL	OxyContin	oral	tablet,oral only,ext.rel.12 hr	40	mg
OXYCODONE HCL	oxycodone	oral	tablet extended release 12 hr	40	mg
OXYCODONE HCL	oxycodone	oral	tablet,oral only,ext.rel.12 hr	40	mg
OXYCODONE HCL	oxycodone	oral	tablet extended release 12 hr	20	mg
OXYCODONE HCL	OxyContin	oral	tablet extended release 12 hr	80	mg
OXYCODONE HCL	OxyContin	oral	tablet extended release 12 hr	40	mg
OXYCODONE HCL	oxycodone	oral	tablet extended release 12 hr	10	mg
OXYCODONE HCL	OxyContin	oral	tablet extended release 12 hr	15	mg
OXYCODONE HCL	OxyContin	oral	tablet extended release 12 hr	60	mg
OXYCODONE HCL	oxycodone	oral	tablet,oral only,ext.rel.12 hr	10	mg
OXYCODONE HCL	OxyContin	oral	tablet extended release 12 hr	20	mg
OXYCODONE HCL	OxyContin	oral	tablet,oral only,ext.rel.12 hr	10	mg
OXYCODONE HCL	oxycodone	oral	tablet extended release 12 hr	80	mg
OXYCODONE HCL	oxycodone	oral	tablet,oral only,ext.rel.12 hr	20	mg
OXYCODONE HCL	OxyContin	oral	tablet extended release 12 hr	30	mg
OXYCODONE HCL	OxyContin	oral	tablet,oral only,ext.rel.12 hr	20	mg
OXYCODONE HCL	OxyContin	oral	tablet,oral only,ext.rel.12 hr	60	mg
OXYCODONE HCL	OxyContin	oral	tablet,oral only,ext.rel.12 hr	30	mg
OXYCODONE HCL	oxycodone	oral	tablet,oral only,ext.rel.12 hr	80	mg
OXYCODONE HCL	OxyContin	oral	tablet,oral only,ext.rel.12 hr	80	mg
OXYCODONE HCL	OxyContin	oral	tablet,oral only,ext.rel.12 hr	15	mg
OXYCODONE HCL	OxyContin	oral	tablet extended release 12 hr	160	mg

Appendix B: List of Drugs used for Incidence Assessment Criteria in this Request

Generic Name	Brand Name	Route	Form	Strength	Unit
Extended-Release and Long-Acting (ER/LA) Opioid Analgesics					
BUPRENORPHINE	Butrans	transdermal	patch weekly	10	mcg/hour
BUPRENORPHINE	Butrans	transdermal	patch weekly	15	mcg/hour
BUPRENORPHINE	Butrans	transdermal	patch weekly	20	mcg/hour
BUPRENORPHINE	Butrans	transdermal	patch weekly	5	mcg/hour
BUPRENORPHINE	Butrans	transdermal	patch weekly	7.5	mcg/hour
FENTANYL	Duragesic	transdermal	patch 72 hour	100	mcg/hr
FENTANYL	fentanyl	transdermal	patch 72 hour	100	mcg/hr
FENTANYL	Duragesic	transdermal	patch 72 hour	12	mcg/hr
FENTANYL	fentanyl	transdermal	patch 72 hour	12	mcg/hr
FENTANYL	Duragesic	transdermal	patch 72 hour	25	mcg/hr
FENTANYL	fentanyl	transdermal	patch 72 hour	25	mcg/hr
FENTANYL	Duragesic	transdermal	patch 72 hour	50	mcg/hr
FENTANYL	fentanyl	transdermal	patch 72 hour	50	mcg/hr
FENTANYL	Duragesic	transdermal	patch 72 hour	75	mcg/hr
FENTANYL	fentanyl	transdermal	patch 72 hour	75	mcg/hr
HYDROCODONE BITARTRATE	Zohydro ER	oral	capsule,extended release 12 hr	10	mg
HYDROCODONE BITARTRATE	Hysingla ER	oral	tablet,oral only,ext.rel.24 hr	100	mg
HYDROCODONE BITARTRATE	Hysingla ER	oral	tablet,oral only,ext.rel.24 hr	120	mg
HYDROCODONE BITARTRATE	Zohydro ER	oral	capsule,extended release 12 hr	15	mg
HYDROCODONE BITARTRATE	Hysingla ER	oral	tablet,oral only,ext.rel.24 hr	20	mg
HYDROCODONE BITARTRATE	Zohydro ER	oral	capsule,extended release 12 hr	20	mg
HYDROCODONE BITARTRATE	Hysingla ER	oral	tablet,oral only,ext.rel.24 hr	30	mg
HYDROCODONE BITARTRATE	Zohydro ER	oral	capsule,extended release 12 hr	30	mg
HYDROCODONE BITARTRATE	Hysingla ER	oral	tablet,oral only,ext.rel.24 hr	40	mg
HYDROCODONE BITARTRATE	Zohydro ER	oral	capsule,extended release 12 hr	40	mg
HYDROCODONE BITARTRATE	Zohydro ER	oral	capsule,extended release 12 hr	50	mg
HYDROCODONE BITARTRATE	Hysingla ER	oral	tablet,oral only,ext.rel.24 hr	60	mg
HYDROCODONE BITARTRATE	Hysingla ER	oral	tablet,oral only,ext.rel.24 hr	80	mg
HYDROMORPHONE HCL	Exalgo ER	oral	tablet extended release 24 hr	12	mg
HYDROMORPHONE HCL	hydromorphone	oral	tablet extended release 24 hr	12	mg

Generic Name	Brand Name	Route	Form	Strength	Unit
HYDROMORPHONE HCL	Palladone	oral	capsule,ext rel. pellets 24 hr	12	mg
HYDROMORPHONE HCL	Exalgo ER	oral	tablet extended release 24 hr	16	mg
HYDROMORPHONE HCL	hydromorphone	oral	tablet extended release 24 hr	16	mg
HYDROMORPHONE HCL	Palladone	oral	capsule,ext rel. pellets 24 hr	16	mg
HYDROMORPHONE HCL	Palladone	oral	capsule,ext rel. pellets 24 hr	24	mg
HYDROMORPHONE HCL	Exalgo ER	oral	tablet extended release 24 hr	32	mg
HYDROMORPHONE HCL	hydromorphone	oral	tablet extended release 24 hr	32	mg
HYDROMORPHONE HCL	Palladone	oral	capsule,ext rel. pellets 24 hr	32	mg
HYDROMORPHONE HCL	Exalgo ER	oral	tablet extended release 24 hr	8	mg
HYDROMORPHONE HCL	hydromorphone	oral	tablet extended release 24 hr	8	mg
METHADONE HCL	Dolophine	oral	tablet	10	mg
METHADONE HCL	methadone	oral	tablet	10	mg
METHADONE HCL	Methadose	oral	tablet	10	mg
METHADONE HCL	methadone	oral	solution	10	mg/5 mL
METHADONE HCL	methadone	oral	concentrate	10	mg/mL
METHADONE HCL	methadone	oral	syringe	10	mg/mL
METHADONE HCL	Methadone Intensol	oral	concentrate	10	mg/mL
METHADONE HCL	Methadose	oral	concentrate	10	mg/mL
METHADONE HCL	Diskets	oral	tablet,soluble	40	mg
METHADONE HCL	methadone	oral	tablet,soluble	40	mg
METHADONE HCL	Methadose	oral	tablet,soluble	40	mg
METHADONE HCL	Dolophine	oral	tablet	5	mg
METHADONE HCL	methadone	oral	tablet	5	mg
METHADONE HCL	Methadose	oral	tablet	5	mg
METHADONE HCL	methadone	oral	solution	5	mg/5 mL
METHADONE HCL	methadone	oral	syringe	5	mg/5 mL
MORPHINE SULFATE	Kadian	oral	capsule,extend.release pellets	10	mg
MORPHINE SULFATE	morphine	oral	capsule,extend.release pellets	10	mg
MORPHINE SULFATE	Kadian	oral	capsule,extend.release pellets	100	mg
MORPHINE SULFATE	morphine	oral	tablet extended release	100	mg
MORPHINE SULFATE	morphine	oral	capsule,extend.release pellets	100	mg
MORPHINE SULFATE	MS Contin	oral	tablet extended release	100	mg
MORPHINE SULFATE	Oramorph SR	oral	tablet extended release	100	mg
MORPHINE SULFATE	Avinza	oral	capsule, ER multiphase 24 hr	120	mg

Generic Name	Brand Name	Route	Form	Strength	Unit
MORPHINE SULFATE	morphine	oral	capsule, ER multiphase 24 hr	120	mg
MORPHINE SULFATE	Kadian	oral	capsule,extend.release pellets	130	mg
MORPHINE SULFATE	morphine	oral	tablet extended release	15	mg
MORPHINE SULFATE	MS Contin	oral	tablet extended release	15	mg
MORPHINE SULFATE	Oramorph SR	oral	tablet extended release	15	mg
MORPHINE SULFATE	Kadian	oral	capsule,extend.release pellets	150	mg
MORPHINE SULFATE	Kadian	oral	capsule,extend.release pellets	20	mg
MORPHINE SULFATE	morphine	oral	capsule,extend.release pellets	20	mg
MORPHINE SULFATE	Kadian	oral	capsule,extend.release pellets	200	mg
MORPHINE SULFATE	morphine	oral	tablet extended release	200	mg
MORPHINE SULFATE	MS Contin	oral	tablet extended release	200	mg
MORPHINE SULFATE	Avinza	oral	capsule, ER multiphase 24 hr	30	mg
MORPHINE SULFATE	Kadian	oral	capsule,extend.release pellets	30	mg
MORPHINE SULFATE	morphine	oral	capsule,extend.release pellets	30	mg
MORPHINE SULFATE	morphine	oral	tablet extended release	30	mg
MORPHINE SULFATE	morphine	oral	capsule, ER multiphase 24 hr	30	mg
MORPHINE SULFATE	MS Contin	oral	tablet extended release	30	mg
MORPHINE SULFATE	Oramorph SR	oral	tablet extended release	30	mg
MORPHINE SULFATE	Kadian	oral	capsule,extend.release pellets	40	mg
MORPHINE SULFATE	Avinza	oral	capsule, ER multiphase 24 hr	45	mg
MORPHINE SULFATE	morphine	oral	capsule, ER multiphase 24 hr	45	mg
MORPHINE SULFATE	Kadian	oral	capsule,extend.release pellets	50	mg
MORPHINE SULFATE	morphine	oral	capsule,extend.release pellets	50	mg
MORPHINE SULFATE	Avinza	oral	capsule, ER multiphase 24 hr	60	mg
MORPHINE SULFATE	Kadian	oral	capsule,extend.release pellets	60	mg
MORPHINE SULFATE	morphine	oral	tablet extended release	60	mg
MORPHINE SULFATE	morphine	oral	capsule,extend.release pellets	60	mg
MORPHINE SULFATE	morphine	oral	capsule, ER multiphase 24 hr	60	mg
MORPHINE SULFATE	MS Contin	oral	tablet extended release	60	mg
MORPHINE SULFATE	Oramorph SR	oral	tablet extended release	60	mg
MORPHINE SULFATE	Kadian	oral	capsule,extend.release pellets	70	mg
MORPHINE SULFATE	Avinza	oral	capsule, ER multiphase 24 hr	75	mg

Generic Name	Brand Name	Route	Form	Strength	Unit
MORPHINE SULFATE	morphine	oral	capsule, ER multiphase 24 hr	75	mg
MORPHINE SULFATE	Kadian	oral	capsule,extend.release pellets	80	mg
MORPHINE SULFATE	morphine	oral	capsule,extend.release pellets	80	mg
MORPHINE SULFATE	Avinza	oral	capsule, ER multiphase 24 hr	90	mg
MORPHINE SULFATE	morphine	oral	capsule, ER multiphase 24 hr	90	mg
MORPHINE SULFATE/NALTREXONE HCL	Embeda	oral	capsule,oral only,ext.rel pell	100-4	mg
MORPHINE SULFATE/NALTREXONE HCL	Embeda	oral	capsule,extend.release pellets	100-4	mg
MORPHINE SULFATE/NALTREXONE HCL	Embeda	oral	capsule,extend.release pellets	20-0.8	mg
MORPHINE SULFATE/NALTREXONE HCL	Embeda	oral	capsule,oral only,ext.rel pell	20-0.8	mg
MORPHINE SULFATE/NALTREXONE HCL	Embeda	oral	capsule,extend.release pellets	30-1.2	mg
MORPHINE SULFATE/NALTREXONE HCL	Embeda	oral	capsule,oral only,ext.rel pell	30-1.2	mg
MORPHINE SULFATE/NALTREXONE HCL	Embeda	oral	capsule,oral only,ext.rel pell	50-2	mg
MORPHINE SULFATE/NALTREXONE HCL	Embeda	oral	capsule,extend.release pellets	50-2	mg
MORPHINE SULFATE/NALTREXONE HCL	Embeda	oral	capsule,extend.release pellets	60-2.4	mg
MORPHINE SULFATE/NALTREXONE HCL	Embeda	oral	capsule,oral only,ext.rel pell	60-2.4	mg
MORPHINE SULFATE/NALTREXONE HCL	Embeda	oral	capsule,oral only,ext.rel pell	80-3.2	mg
MORPHINE SULFATE/NALTREXONE HCL	Embeda	oral	capsule,extend.release pellets	80-3.2	mg
OXYCODONE HCL	oxycodone	oral	tablet extended release 12 hr	10	mg
OXYCODONE HCL	oxycodone	oral	tablet,oral only,ext.rel.12 hr	10	mg
OXYCODONE HCL	OxyContin	oral	tablet extended release 12 hr	10	mg
OXYCODONE HCL	OxyContin	oral	tablet,oral only,ext.rel.12 hr	10	mg
OXYCODONE HCL	OxyContin	oral	tablet extended release 12 hr	15	mg
OXYCODONE HCL	OxyContin	oral	tablet,oral only,ext.rel.12 hr	15	mg
OXYCODONE HCL	OxyContin	oral	tablet extended release 12 hr	160	mg
OXYCODONE HCL	oxycodone	oral	tablet extended release 12 hr	20	mg
OXYCODONE HCL	oxycodone	oral	tablet,oral only,ext.rel.12 hr	20	mg
OXYCODONE HCL	OxyContin	oral	tablet extended release 12 hr	20	mg
OXYCODONE HCL	OxyContin	oral	tablet,oral only,ext.rel.12 hr	20	mg
OXYCODONE HCL	OxyContin	oral	tablet extended release 12 hr	30	mg
OXYCODONE HCL	OxyContin	oral	tablet,oral only,ext.rel.12 hr	30	mg
OXYCODONE HCL	oxycodone	oral	tablet extended release 12 hr	40	mg
OXYCODONE HCL	oxycodone	oral	tablet,oral only,ext.rel.12 hr	40	mg

Generic Name	Brand Name	Route	Form	Strength	Unit
OXYCODONE HCL	OxyContin	oral	tablet,oral only,ext.rel.12 hr	40	mg
OXYCODONE HCL	OxyContin	oral	tablet extended release 12 hr	40	mg
OXYCODONE HCL	OxyContin	oral	tablet extended release 12 hr	60	mg
OXYCODONE HCL	OxyContin	oral	tablet,oral only,ext.rel.12 hr	60	mg
OXYCODONE HCL	oxycodone	oral	tablet extended release 12 hr	80	mg
OXYCODONE HCL	oxycodone	oral	tablet,oral only,ext.rel.12 hr	80	mg
OXYCODONE HCL	OxyContin	oral	tablet extended release 12 hr	80	mg
OXYCODONE HCL	OxyContin	oral	tablet,oral only,ext.rel.12 hr	80	mg
OXYMORPHONE HCL	Opana ER	oral	tablet extended release 12 hr	10	mg
OXYMORPHONE HCL	Opana ER	oral	tablet,oral only,ext.rel.12 hr	10	mg
OXYMORPHONE HCL	oxymorphone	oral	tablet extended release 12 hr	10	mg
OXYMORPHONE HCL	Opana ER	oral	tablet extended release 12 hr	15	mg
OXYMORPHONE HCL	Opana ER	oral	tablet,oral only,ext.rel.12 hr	15	mg
OXYMORPHONE HCL	oxymorphone	oral	tablet extended release 12 hr	15	mg
OXYMORPHONE HCL	Opana ER	oral	tablet,oral only,ext.rel.12 hr	20	mg
OXYMORPHONE HCL	Opana ER	oral	tablet extended release 12 hr	20	mg
OXYMORPHONE HCL	oxymorphone	oral	tablet extended release 12 hr	20	mg
OXYMORPHONE HCL	Opana ER	oral	tablet,oral only,ext.rel.12 hr	30	mg
OXYMORPHONE HCL	Opana ER	oral	tablet extended release 12 hr	30	mg
OXYMORPHONE HCL	oxymorphone	oral	tablet extended release 12 hr	30	mg
OXYMORPHONE HCL	Opana ER	oral	tablet extended release 12 hr	40	mg
OXYMORPHONE HCL	Opana ER	oral	tablet,oral only,ext.rel.12 hr	40	mg
OXYMORPHONE HCL	oxymorphone	oral	tablet extended release 12 hr	40	mg
OXYMORPHONE HCL	Opana ER	oral	tablet,oral only,ext.rel.12 hr	5	mg
OXYMORPHONE HCL	Opana ER	oral	tablet extended release 12 hr	5	mg
OXYMORPHONE HCL	oxymorphone	oral	tablet extended release 12 hr	5	mg
OXYMORPHONE HCL	Opana ER	oral	tablet,oral only,ext.rel.12 hr	7.5	mg
OXYMORPHONE HCL	Opana ER	oral	tablet extended release 12 hr	7.5	mg
OXYMORPHONE HCL	oxymorphone	oral	tablet extended release 12 hr	7.5	mg
TAPENTADOL HCL	Nucynta ER	oral	tablet extended release 12 hr	100	mg
TAPENTADOL HCL	Nucynta ER	oral	tablet extended release 12 hr	150	mg
TAPENTADOL HCL	Nucynta ER	oral	tablet extended release 12 hr	200	mg



Generic Name	Brand Name	Route	Form	Strength	Unit
TAPENTADOL HCL	Nucynta ER	oral	tablet extended release 12 hr	250	mg
TAPENTADOL HCL	Nucynta ER	oral	tablet extended release 12 hr	50	mg

Appendix C: List of Healthcare Common Procedure Coding System (HCPCS) and Current Procedural Terminology, Fourth Revision (CPT-4) Procedure Codes used for Drug Screens in this Request

Code	Description	Code Type	Care Setting
Drug Screens			
G0430	Drug screen, qualitative; multiple drug classes, other than chromatographic method, each procedure	HCPCS	Any
G0431	Drug screen, qualitative; single drug class method (e.g., immunoassay, and enzyme assay), each drug class	HCPCS	Any
G0434	Drug screen, other than chromatographic; any number of drug classes, by CLIA waived test or moderate complexity test, per patient encounter	HCPCS	Any
80100	Drug screen, qualitative; multiple drug classes chromatographic method, each procedure	CPT-4	Any
80101	Drug screen, qualitative; single drug class method (eg, immunoassay, enzyme assay), each drug class	CPT-4	Any
80104	Drug screen, qualitative; multiple drug classes, other than chromatographic method, each procedure	CPT-4	Any
82486	Chromatography, qualitative; column (eg, gas liquid or HPLC), analyte not elsewhere specified	CPT-4	Any
82491	Chromatography, quantitative, column (eg, gas liquid or HPLC); single analyte not elsewhere specified, single stationary and mobile phase	CPT-4	Any
82492	Chromatography, quantitative, column (eg, gas liquid or HPLC); multiple analytes, single stationary and mobile phase	CPT-4	Any
82541	Column chromatography/mass spectrometry (eg, GC/MS, or HPLC/MS), analyte not elsewhere specified; qualitative, single stationary and mobile phase	CPT-4	Any
82542	Column chromatography/mass spectrometry (eg, GC/MS, or HPLC/MS), analyte not elsewhere specified; quantitative, single stationary and mobile phase	CPT-4	Any
82543	Column chromatography/mass spectrometry (eg, GC/MS, or HPLC/MS), analyte not elsewhere specified; stable isotope dilution, single analyte, quantitative, single stationary and mobile phase	CPT-4	Any
82544	Column chromatography/mass spectrometry (eg, GC/MS, or HPLC/MS), analyte not elsewhere specified; stable isotope dilution, multiple analytes, quantitative, single stationary and mobile phase	CPT-4	Any
83788	Mass spectrometry and tandem mass spectrometry (MS, MS/MS), analyte not elsewhere specified; qualitative, each specimen	CPT-4	Any
83789	Mass spectrometry and tandem mass spectrometry (MS, MS/MS), analyte not elsewhere specified; quantitative, each specimen	CPT-4	Any
83925	Opiate(s), drug and metabolites, each procedure	CPT-4	Any

Appendix D1: List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) Diagnosis Codes used for Exclusions in this Request

Code	Description	Code Type	Care Setting
Opioid Poisoning			
965.0	Poisoning by opiates and related narcotics	ICD-9-CM Diagnosis Code	Inpatient or Outpatient
965.00	Poisoning by opium (alkaloids), unspecified	ICD-9-CM Diagnosis Code	Inpatient or Outpatient
965.01	Poisoning by heroin	ICD-9-CM Diagnosis Code	Inpatient or Outpatient
965.02	Poisoning by methadone	ICD-9-CM Diagnosis Code	Inpatient or Outpatient
965.09	Poisoning by other opiates and related narcotics	ICD-9-CM Diagnosis Code	Inpatient or Outpatient

Appendix D2: List of Drugs used for Inclusions/Exclusions in this Request

Generic Name	Brand Name	Route	Form	Strength	Unit
Immediate Release (IR) Opioid Analgesics					
ACETAMINOPHEN WITH CODEINE PHOSPHATE	acetaminophen-codeine	oral	solution	120 mg-12 mg	/5 mL (5 mL)
ACETAMINOPHEN WITH CODEINE PHOSPHATE	acetaminophen-codeine	oral	solution	120-12	mg/5 mL
ACETAMINOPHEN WITH CODEINE PHOSPHATE	acetaminophen-codeine	oral	elixir	120-12	mg/5 mL
ACETAMINOPHEN WITH CODEINE PHOSPHATE	Capital with Codeine	oral	suspension	120-12	mg/5 mL
ACETAMINOPHEN WITH CODEINE PHOSPHATE	Tylenol-Codeine Elixir	oral	elixir	120-12	mg/5 mL
ACETAMINOPHEN WITH CODEINE PHOSPHATE	acetaminophen-codeine	oral	solution	240 mg-24 mg	/10 mL (10 mL)
ACETAMINOPHEN WITH CODEINE PHOSPHATE	acetaminophen-codeine	oral	solution	300 mg-30 mg	/12.5 mL
ACETAMINOPHEN WITH CODEINE PHOSPHATE	acetaminophen-codeine	oral	tablet	300-15	mg
ACETAMINOPHEN WITH CODEINE PHOSPHATE	acetaminophen-codeine	oral	tablet	300-30	mg
ACETAMINOPHEN WITH CODEINE PHOSPHATE	Tylenol-Codeine #3	oral	tablet	300-30	mg
ACETAMINOPHEN WITH CODEINE PHOSPHATE	acetaminophen-codeine	oral	tablet	300-60	mg
ACETAMINOPHEN WITH CODEINE PHOSPHATE	Tylenol-Codeine #4	oral	tablet	300-60	mg
ACETAMINOPHEN WITH CODEINE PHOSPHATE	Phenaphen/Codeine #3	oral	capsule	325-30	mg
ACETAMINOPHEN WITH CODEINE PHOSPHATE	Phenaphen/Codeine #4	oral	capsule	325-60	mg
ACETAMINOPHEN WITH CODEINE PHOSPHATE	acetaminophen-codeine	oral	solution	360 mg-36 mg	/15 mL (15 mL)
ACETAMINOPHEN WITH CODEINE PHOSPHATE	Cocet	oral	tablet	650-30	mg
ACETAMINOPHEN WITH CODEINE PHOSPHATE	Vopac	oral	tablet	650-30	mg
ACETAMINOPHEN WITH CODEINE PHOSPHATE	Cocet Plus	oral	tablet	650-60	mg
ASPIRIN/CODEINE PHOSPHATE	aspirin-codeine	oral	tablet	325-30	mg
ASPIRIN/CODEINE PHOSPHATE	Aspirin-Codeine #3	oral	tablet	325-30	mg
ASPIRIN/CODEINE PHOSPHATE	Aspirin-Codeine #4	oral	tablet	325-60	mg
BUTALBITAL/ACETAMINOPHEN/CAFFEINE/CODEINE PHOSPHATE	butalbital-acetaminop-caf-cod	oral	capsule	50-300-40-30	mg
BUTALBITAL/ACETAMINOPHEN/CAFFEINE/CODEINE PHOSPHATE	Fioricet with Codeine	oral	capsule	50-300-40-30	mg
BUTALBITAL/ACETAMINOPHEN/CAFFEINE/CODEINE PHOSPHATE	butalbital-acetaminop-caf-cod	oral	capsule	50-325-40-30	mg
BUTALBITAL/ACETAMINOPHEN/CAFFEINE/CODEINE PHOSPHATE	Fioricet with Codeine	oral	capsule	50-325-40-30	mg
BUTALBITAL/ACETAMINOPHEN/CAFFEINE/CODEINE PHOSPHATE	Phrenilin w/Caffeine-Codeine	oral	capsule	50-325-40-30	mg

Generic Name	Brand Name	Route	Form	Strength	Unit
CODEINE PHOSPHATE	codeine phosphate	oral	solution	15	mg/5 mL
CODEINE PHOSPHATE/BUTALBITAL/ASPIRIN/CAFFEINE	Ascomp with Codeine	oral	capsule	30-50-325-40	mg
CODEINE PHOSPHATE/BUTALBITAL/ASPIRIN/CAFFEINE	Butalbital Compound W/Codeine	oral	capsule	30-50-325-40	mg
CODEINE PHOSPHATE/BUTALBITAL/ASPIRIN/CAFFEINE	Butalbital Compound-Codeine	oral	capsule	30-50-325-40	mg
CODEINE PHOSPHATE/BUTALBITAL/ASPIRIN/CAFFEINE	codeine-butalbital-ASA-caff	oral	capsule	30-50-325-40	mg
CODEINE PHOSPHATE/BUTALBITAL/ASPIRIN/CAFFEINE	Fiorinal-Codeine #3	oral	capsule	30-50-325-40	mg
CODEINE PHOSPHATE/BUTALBITAL/ASPIRIN/CAFFEINE	Fiortal/Codeine	oral	capsule	30-50-325-40	mg
CODEINE PHOSPHATE/CARISOPRODOL/ASPIRIN	Carisoprodol Compound-Codeine	oral	tablet	200-325-16	mg
CODEINE PHOSPHATE/CARISOPRODOL/ASPIRIN	carisoprodol-ASA-codeine	oral	tablet	200-325-16	mg
CODEINE PHOSPHATE/CARISOPRODOL/ASPIRIN	Soma Compound with Codeine	oral	tablet	200-325-16	mg
CODEINE SULFATE	codeine sulfate	oral	tablet	15	mg
CODEINE SULFATE	codeine sulfate	oral	solution	15 mg/2.5 mL	(2.5 mL)
CODEINE SULFATE	codeine sulfate	oral	tablet	30	mg
CODEINE SULFATE	codeine sulfate	oral	solution	30	mg/5 mL
CODEINE SULFATE	codeine sulfate	oral	solution	30 mg/5 mL	(5 mL)
CODEINE SULFATE	codeine sulfate	oral	tablet	60	mg
CODEINE/ASPIRIN/SALICYLAMIDE/ACETAMINOPHEN/ CAFFEINE	Rid-A-Pain	oral	tablet		
CODEINE/ASPIRIN/SALICYLAMIDE/ACETAMINOPHEN/ CAFFEINE	Rid-A-Pain W/Codeine	oral	tablet	227-97-32-32-1	mg
CODEINE/ASPIRIN/SALICYLAMIDE/ACETAMINOPHEN/ CAFFEINE	Trezix	oral	capsule	16-320.5-30	mg
CODEINE/ASPIRIN/SALICYLAMIDE/ACETAMINOPHEN/ CAFFEINE	DHC Plus	oral	capsule	16-356.4-30	mg
CODEINE/ASPIRIN/SALICYLAMIDE/ACETAMINOPHEN/ CAFFEINE	Panlor DC	oral	capsule	16-356.4-30	mg
CODEINE/ASPIRIN/SALICYLAMIDE/ACETAMINOPHEN/ CAFFEINE	Trezix	oral	capsule	16-356.4-30	mg
CODEINE/ASPIRIN/SALICYLAMIDE/ACETAMINOPHEN/ CAFFEINE	dihydrocode-acetaminophen-caff	oral	tablet	32-712.8-60	mg
CODEINE/ASPIRIN/SALICYLAMIDE/ACETAMINOPHEN/ CAFFEINE	Panlor SS	oral	tablet	32-712.8-60	mg
CODEINE/ASPIRIN/SALICYLAMIDE/ACETAMINOPHEN/ CAFFEINE	Zerlor	oral	tablet	32-712.8-60	mg

Generic Name	Brand Name	Route	Form	Strength	Unit
DIHYDROCODEINE BITARTRATE/ASPIRIN/CAFFEINE	dihydrocodeine-aspirin-caff	oral	capsule	16-356.4-30	mg
DIHYDROCODEINE BITARTRATE/ASPIRIN/CAFFEINE	Synalgos-DC	oral	capsule	16-356.4-30	mg
DIHYDROCODEINE/ASPIRIN/CAFFEINE	Synalgos-DC	oral	capsule		
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Stagesic-10	oral	tablet	10-250	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	10-300	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Vicodin HP	oral	tablet	10-300	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Xodol 10/300	oral	tablet	10-300	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lortab Elixir	oral	solution	10-300	mg/15 mL
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Zolvit	oral	solution	10-300	mg/15 mL
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	10-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lorcet HD	oral	tablet	10-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lortab 10-325	oral	tablet	10-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Norco	oral	tablet	10-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Zamicet	oral	solution	10-325	mg/15 mL
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	solution	10-325	mg/15 mL(15 mL)
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Zydone	oral	tablet	10-400	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	10-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lortab	oral	tablet	10-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Hycomed	oral	tablet	10-650	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	10-650	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lorcet 10/650	oral	tablet	10-650	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Anexsia	oral	tablet	10-660	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	10-660	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Vicodin HP	oral	tablet	10-660	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	10-750	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Maxidone	oral	tablet	10-750	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	elixir	2.5-167	mg/5 mL
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	solution	2.5-167	mg/5 mL
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lortab	oral	elixir	2.5-167	mg/5 mL
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	2.5-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Verdrocet	oral	tablet	2.5-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	2.5-500	mg

Generic Name	Brand Name	Route	Form	Strength	Unit
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lortab	oral	tablet	2.5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Liquicet	oral	solution	3.33-167	mg/5 mL
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	solution	5-163	mg/7.5mL(7.5mL)
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	5-300	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Vicodin	oral	tablet	5-300	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Xodol 5/300	oral	tablet	5-300	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Anexsia	oral	tablet	5-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	5-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lorcet (hydrocodone)	oral	tablet	5-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lortab 5-325	oral	tablet	5-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Norco	oral	tablet	5-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Procet	oral	tablet	5-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	solution	5-334	mg/10 mL
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Zydone	oral	tablet	5-400	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Anexsia	oral	tablet	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Bancap HC	oral	capsule	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Ceta Plus	oral	capsule	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Co-Gesic	oral	tablet	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Dolacet	oral	capsule	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Dolorex Forte	oral	capsule	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Duocet	oral	tablet	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Hycomed	oral	tablet	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Hydrocet	oral	capsule	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	capsule	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Hydrogesic	oral	capsule	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Hy-Phen	oral	tablet	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lorcet HD	oral	capsule	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lortab	oral	tablet	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Margesic-H	oral	capsule	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Polygesic	oral	capsule	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Stagesic	oral	capsule	5-500	mg

Generic Name	Brand Name	Route	Form	Strength	Unit
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Vanacet	oral	tablet	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Vendone	oral	capsule	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Vicodin	oral	tablet	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	7.5-300	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Vicodin ES	oral	tablet	7.5-300	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Xodol 7.5/300	oral	tablet	7.5-300	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Anexsia	oral	tablet	7.5-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	7.5-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lorcet Plus	oral	tablet	7.5-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lortab 7.5-325	oral	tablet	7.5-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Norco	oral	tablet	7.5-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Procet	oral	tablet	7.5-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Hycet	oral	solution	7.5-325	mg/15 mL
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	solution	7.5-325	mg/15 mL
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Zydone	oral	tablet	7.5-400	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	7.5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lortab	oral	tablet	7.5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	solution	7.5-500	mg/15 mL
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lortab Elixir	oral	solution	7.5-500	mg/15 mL
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	solution	7.5-500	mg/15 mL(15 mL)
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Anexsia	oral	tablet	7.5-650	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	7.5-650	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lorcet Plus	oral	tablet	7.5-650	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	7.5-750	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Vicodin ES	oral	tablet	7.5-750	mg
	Theracodophen-325				
HYDROCODONE BITARTRATE/ACETAMINOPHEN/DIETARY SUPPLEMENT #11		oral	combo pack	10-325	mg
	Theracodophen-650				
HYDROCODONE BITARTRATE/ACETAMINOPHEN/DIETARY SUPPLEMENT #11		oral	combo pack	10-650	mg

Generic Name	Brand Name	Route	Form	Strength	Unit
	Theracodophen-Low-90				
HYDROCODONE BITARTRATE/ACETAMINOPHEN/DIETARY SUPPLEMENT #11		oral	combo pack	5-500	mg
HYDROCODONE BITARTRATE/ASPIRIN	Alor	oral	tablet	5-500	mg
HYDROCODONE BITARTRATE/ASPIRIN	Damason-P	oral	tablet	5-500	mg
HYDROCODONE BITARTRATE/ASPIRIN	Lortab ASA	oral	tablet	5-500	mg
HYDROCODONE/IBUPROFEN	hydrocodone-ibuprofen	oral	tablet	10-200	mg
HYDROCODONE/IBUPROFEN	Ibudone	oral	tablet	10-200	mg
HYDROCODONE/IBUPROFEN	Reprexain	oral	tablet	10-200	mg
HYDROCODONE/IBUPROFEN	Xylon 10	oral	tablet	10-200	mg
HYDROCODONE/IBUPROFEN	hydrocodone-ibuprofen	oral	tablet	2.5-200	mg
HYDROCODONE/IBUPROFEN	Reprexain	oral	tablet	2.5-200	mg
HYDROCODONE/IBUPROFEN	hydrocodone-ibuprofen	oral	tablet	5-200	mg
HYDROCODONE/IBUPROFEN	Ibudone	oral	tablet	5-200	mg
HYDROCODONE/IBUPROFEN	Reprexain	oral	tablet	5-200	mg
HYDROCODONE/IBUPROFEN	hydrocodone-ibuprofen	oral	tablet	7.5-200	mg
HYDROCODONE/IBUPROFEN	Reprexain	oral	tablet	7.5-200	mg
HYDROCODONE/IBUPROFEN	Vicoprofen	oral	tablet	7.5-200	mg
HYDROMORPHONE HCL	Dilaudid	oral	liquid	1	mg/mL
HYDROMORPHONE HCL	Dilaudid-5	oral	liquid	1	mg/mL
HYDROMORPHONE HCL	hydromorphone	oral	liquid	1	mg/mL
HYDROMORPHONE HCL	Dilaudid	oral	tablet	2	mg
HYDROMORPHONE HCL	hydromorphone	oral	tablet	2	mg
HYDROMORPHONE HCL	Dilaudid	oral	tablet	4	mg
HYDROMORPHONE HCL	hydromorphone	oral	tablet	4	mg
HYDROMORPHONE HCL	Dilaudid	oral	tablet	8	mg
HYDROMORPHONE HCL	hydromorphone	oral	tablet	8	mg
IBUPROFEN/OXYCODONE HCL	Combunox	oral	tablet	400-5	mg
IBUPROFEN/OXYCODONE HCL	ibuprofen-oxycodone	oral	tablet	400-5	mg
LEVOMETHADYL ACETATE HCL	Orlaam	oral	solution	10	mg/mL
LEVORPHANOL TARTRATE	Levo-Dromoran	oral	tablet	2	mg
LEVORPHANOL TARTRATE	levorphanol tartrate	oral	tablet	2	mg
MEPERIDINE HCL	Demerol	oral	tablet	100	mg

Generic Name	Brand Name	Route	Form	Strength	Unit
MEPERIDINE HCL	meperidine	oral	tablet	100	mg
MEPERIDINE HCL	Meperitab	oral	tablet	100	mg
MEPERIDINE HCL	Demerol	oral	tablet	50	mg
MEPERIDINE HCL	meperidine	oral	tablet	50	mg
MEPERIDINE HCL	Meperitab	oral	tablet	50	mg
MEPERIDINE HCL	Demerol	oral	solution	50	mg/5 mL
MEPERIDINE HCL	meperidine	oral	solution	50	mg/5 mL
MORPHINE SULFATE	morphine concentrate	oral	solution	10	mg/0.5 mL
MORPHINE SULFATE	morphine	oral	solution	10	mg/5 mL
MORPHINE SULFATE	MSir	oral	solution	10	mg/5 mL
MORPHINE SULFATE	morphine concentrate	oral	solution	100 mg/5 mL	(20 mg/mL)
MORPHINE SULFATE	MSir Concentrate	oral	solution	100 mg/5 mL	(20 mg/mL)
MORPHINE SULFATE	Roxanol Concentrate	oral	solution	100 mg/5 mL	(20 mg/mL)
MORPHINE SULFATE	Roxanol-T Concentrate	oral	solution	100 mg/5 mL	(20 mg/mL)
MORPHINE SULFATE	morphine	oral	tablet	15	mg
MORPHINE SULFATE	MSir	oral	capsule	15	mg
MORPHINE SULFATE	MSir	oral	tablet	15	mg
MORPHINE SULFATE	morphine	oral	solution	20	mg/5 mL
MORPHINE SULFATE	MSir	oral	solution	20	mg/5 mL
MORPHINE SULFATE	morphine concentrate	oral	syringe	20	mg/mL
MORPHINE SULFATE	morphine	oral	tablet	30	mg
MORPHINE SULFATE	MSir	oral	tablet	30	mg
MORPHINE SULFATE	MSir	oral	capsule	30	mg
MORPHINE SULFATE	morphine concentrate	oral	solution	5	mg/0.25 mL
OPIUM TINCTURE	opium tincture	oral	tincture	10 mg/mL	(morphine)
OPIUM TINCTURE	opium tincture	oral	syringe	10 mg/mL	(morphine)
OXYCODONE HCL	Dazidox	oral	tablet	10	mg
OXYCODONE HCL	oxycodone	oral	tablet	10	mg
OXYCODONE HCL	oxycodone	oral	tablet	15	mg
OXYCODONE HCL	Roxicodone	oral	tablet	15	mg
OXYCODONE HCL	Dazidox	oral	tablet	20	mg
OXYCODONE HCL	oxycodone	oral	tablet	20	mg

Generic Name	Brand Name	Route	Form	Strength	Unit
OXYCODONE HCL	ETH-Oxydose	oral	concentrate	20	mg/mL
OXYCODONE HCL	oxycodone	oral	concentrate	20	mg/mL
OXYCODONE HCL	Oxyfast	oral	concentrate	20	mg/mL
OXYCODONE HCL	Roxicodone Intensol	oral	concentrate	20	mg/mL
OXYCODONE HCL	ETH-Oxydose	oral	concentrate	20	mg/mL (1 mL)
OXYCODONE HCL	oxycodone	oral	tablet	30	mg
OXYCODONE HCL	Roxicodone	oral	tablet	30	mg
OXYCODONE HCL	Endocodone	oral	tablet	5	mg
OXYCODONE HCL	Oxecta	oral	tablet, oral or	5	mg
OXYCODONE HCL	oxycodone	oral	tablet	5	mg
OXYCODONE HCL	oxycodone	oral	capsule	5	mg
OXYCODONE HCL	OxyIR	oral	capsule	5	mg
OXYCODONE HCL	Percolone	oral	tablet	5	mg
OXYCODONE HCL	Roxicodone	oral	tablet	5	mg
OXYCODONE HCL	oxycodone	oral	solution	5	mg/5 mL
OXYCODONE HCL	Roxicodone	oral	solution	5	mg/5 mL
OXYCODONE HCL	Oxecta	oral	tablet, oral or	7.5	mg
OXYCODONE HCL/ACETAMINOPHEN	Lynox	oral	tablet	10-300	mg
OXYCODONE HCL/ACETAMINOPHEN	Perloxx	oral	tablet	10-300	mg
OXYCODONE HCL/ACETAMINOPHEN	Primlev	oral	tablet	10-300	mg
OXYCODONE HCL/ACETAMINOPHEN	Endocet	oral	tablet	10-325	mg
OXYCODONE HCL/ACETAMINOPHEN	oxycodone-acetaminophen	oral	tablet	10-325	mg
OXYCODONE HCL/ACETAMINOPHEN	Percocet	oral	tablet	10-325	mg
OXYCODONE HCL/ACETAMINOPHEN	Magnacet	oral	tablet	10-400	mg
OXYCODONE HCL/ACETAMINOPHEN	ALCET	oral	tablet	10-500	mg
OXYCODONE HCL/ACETAMINOPHEN	Narvox	oral	tablet	10-500	mg
OXYCODONE HCL/ACETAMINOPHEN	Xolox	oral	tablet	10-500	mg
OXYCODONE HCL/ACETAMINOPHEN	Endocet	oral	tablet	10-650	mg
OXYCODONE HCL/ACETAMINOPHEN	oxycodone-acetaminophen	oral	tablet	10-650	mg
OXYCODONE HCL/ACETAMINOPHEN	Percocet	oral	tablet	10-650	mg
OXYCODONE HCL/ACETAMINOPHEN	Lynox	oral	tablet	2.5-300	mg
OXYCODONE HCL/ACETAMINOPHEN	Perloxx	oral	tablet	2.5-300	mg

Generic Name	Brand Name	Route	Form	Strength	Unit
OXYCODONE HCL/ACETAMINOPHEN	Primalev	oral	tablet	2.5-300	mg
OXYCODONE HCL/ACETAMINOPHEN	Endocet	oral	tablet	2.5-325	mg
OXYCODONE HCL/ACETAMINOPHEN	oxycodone-acetaminophen	oral	tablet	2.5-325	mg
OXYCODONE HCL/ACETAMINOPHEN	Percocet	oral	tablet	2.5-325	mg
OXYCODONE HCL/ACETAMINOPHEN	Magnacet	oral	tablet	2.5-400	mg
OXYCODONE HCL/ACETAMINOPHEN	Lynox	oral	tablet	5-300	mg
OXYCODONE HCL/ACETAMINOPHEN	Perloxx	oral	tablet	5-300	mg
OXYCODONE HCL/ACETAMINOPHEN	Primlev	oral	tablet	5-300	mg
OXYCODONE HCL/ACETAMINOPHEN	Endocet	oral	tablet	5-325	mg
OXYCODONE HCL/ACETAMINOPHEN	oxycodone-acetaminophen	oral	tablet	5-325	mg
OXYCODONE HCL/ACETAMINOPHEN	Percocet	oral	tablet	5-325	mg
OXYCODONE HCL/ACETAMINOPHEN	Roxicet	oral	tablet	5-325	mg
OXYCODONE HCL/ACETAMINOPHEN	oxycodone-acetaminophen	oral	solution	5-325	mg/5 mL
OXYCODONE HCL/ACETAMINOPHEN	Roxicet	oral	solution	5-325	mg/5 mL
OXYCODONE HCL/ACETAMINOPHEN	Magnacet	oral	tablet	5-400	mg
OXYCODONE HCL/ACETAMINOPHEN	oxycodone-acetaminophen	oral	capsule	5-500	mg
OXYCODONE HCL/ACETAMINOPHEN	Roxicet	oral	tablet	5-500	mg
OXYCODONE HCL/ACETAMINOPHEN	Tylox	oral	capsule	5-500	mg
OXYCODONE HCL/ACETAMINOPHEN	Lynox	oral	tablet	7.5-300	mg
OXYCODONE HCL/ACETAMINOPHEN	Perloxx	oral	tablet	7.5-300	mg
OXYCODONE HCL/ACETAMINOPHEN	Primlev	oral	tablet	7.5-300	mg
OXYCODONE HCL/ACETAMINOPHEN	Endocet	oral	tablet	7.5-325	mg
OXYCODONE HCL/ACETAMINOPHEN	oxycodone-acetaminophen	oral	tablet	7.5-325	mg
OXYCODONE HCL/ACETAMINOPHEN	Percocet	oral	tablet	7.5-325	mg
OXYCODONE HCL/ACETAMINOPHEN	Xartemis XR	oral	tab,oral only,	7.5-325	mg
OXYCODONE HCL/ACETAMINOPHEN	Magnacet	oral	tablet	7.5-400	mg
OXYCODONE HCL/ACETAMINOPHEN	Endocet	oral	tablet	7.5-500	mg
OXYCODONE HCL/ACETAMINOPHEN	oxycodone-acetaminophen	oral	tablet	7.5-500	mg
OXYCODONE HCL/ACETAMINOPHEN	Percocet	oral	tablet	7.5-500	mg
OXYCODONE HCL/ASPIRIN	Endodan	oral	tablet	4.8355-325	mg
OXYCODONE HCL/ASPIRIN	oxycodone-aspirin	oral	tablet	4.8355-325	mg
OXYCODONE HCL/ASPIRIN	Percodan	oral	tablet	4.8355-325	mg

Generic Name	Brand Name	Route	Form	Strength	Unit
OXYCODONE HCL/OXYCODONE TEREPHTHALATE/ASPIRIN	Endodan (Old Formula)	oral	tablet	4.5-0.38-325	mg
OXYCODONE HCL/OXYCODONE TEREPHTHALATE/ASPIRIN	oxycodone HCl-oxycodone-ASA	oral	tablet	4.5-0.38-325	mg
OXYCODONE HCL/OXYCODONE TEREPHTHALATE/ASPIRIN	Percodan	oral	tablet	4.5-0.38-325	mg
OXYCODONE/ASPIRIN	Percodan Demi	oral	tablet	2.44-325	mg
OXYMORPHONE HCL	Opana	oral	tablet	10	mg
OXYMORPHONE HCL	oxymorphone	oral	tablet	10	mg
OXYMORPHONE HCL	Opana	oral	tablet	5	mg
OXYMORPHONE HCL	oxymorphone	oral	tablet	5	mg
PROPOXYPHENE HCL	Darvon	oral	capsule	65	mg
PROPOXYPHENE HCL	PP-Cap	oral	capsule	65	mg
PROPOXYPHENE HCL	propoxyphene	oral	capsule	65	mg
PROPOXYPHENE HCL/ACETAMINOPHEN	propoxyphene-acetaminophen	oral	tablet	65-650	mg
PROPOXYPHENE HCL/ACETAMINOPHEN	Wygesic	oral	tablet	65-650	mg
PROPOXYPHENE HCL/ASPIRIN/CAFFEINE	Darvon Compound 32	oral	capsule	32-389-32.4	mg
PROPOXYPHENE HCL/ASPIRIN/CAFFEINE	Darvon Compound-65	oral	capsule	65-389-32.4	mg
PROPOXYPHENE HCL/ASPIRIN/CAFFEINE	PC-Cap	oral	capsule	65-389-32.4	mg
PROPOXYPHENE HCL/ASPIRIN/CAFFEINE	Propoxyphene Compound-65	oral	capsule	65-389-32.4	mg
PROPOXYPHENE NAPSYLATE	Darvon-N	oral	tablet	100	mg
PROPOXYPHENE NAPSYLATE	propoxyphene napsylate	oral	tablet	100	mg
PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN	Balacet 325	oral	tablet	100-325	mg
PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN	propoxyphene N-acetaminophen	oral	tablet	100-325	mg
PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN	Trycet	oral	tablet	100-325	mg
PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN	Darvocet A500	oral	tablet	100-500	mg
PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN	propoxyphene N-acetaminophen	oral	tablet	100-500	mg
PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN	Darvocet-N 100	oral	tablet	100-650	mg
PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN	Propoxacet-N 100	oral	tablet	100-650	mg
PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN	propoxyphene N-acetaminophen	oral	tablet	100-650	mg
PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN	Darvocet-N 50	oral	tablet	50-325	mg
PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN	propoxyphene N-acetaminophen	oral	tablet	50-325	mg
TAPENTADOL HCL	Nucynta	oral	tablet	100	mg
TAPENTADOL HCL	Nucynta	oral	tablet	50	mg
TAPENTADOL HCL	Nucynta	oral	tablet	75	mg

Generic Name	Brand Name	Route	Form	Strength	Unit
TRAMADOL HCL	ConZip	oral	capsule,ER bi	100	mg
TRAMADOL HCL	Ryzolt	oral	tablet, ER mu	100	mg
TRAMADOL HCL	tramadol	oral	tablet extend	100	mg
TRAMADOL HCL	tramadol	oral	tablet, ER mu	100	mg
TRAMADOL HCL	Ultram ER	oral	tablet extend	100	mg
TRAMADOL HCL	tramadol	oral	capsule,ER bi	150	mg
TRAMADOL HCL	ConZip	oral	capsule,ER bi	200	mg
TRAMADOL HCL	Ryzolt	oral	tablet, ER mu	200	mg
TRAMADOL HCL	tramadol	oral	tablet extend	200	mg
TRAMADOL HCL	tramadol	oral	tablet, ER mu	200	mg
TRAMADOL HCL	Ultram ER	oral	tablet extend	200	mg
TRAMADOL HCL	ConZip	oral	capsule,ER bi	300	mg
TRAMADOL HCL	Ryzolt	oral	tablet, ER mu	300	mg
TRAMADOL HCL	tramadol	oral	tablet, ER mu	300	mg
TRAMADOL HCL	tramadol	oral	tablet extend	300	mg
TRAMADOL HCL	Ultram ER	oral	tablet extend	300	mg
TRAMADOL HCL	Rybix ODT	oral	tablet,disinte	50	mg
TRAMADOL HCL	tramadol	oral	tablet	50	mg
TRAMADOL HCL	Ultram	oral	tablet	50	mg
TRAMADOL HCL/ACETAMINOPHEN	tramadol-acetaminophen	oral	tablet	37.5-325	mg
TRAMADOL HCL/ACETAMINOPHEN	Ultracet	oral	tablet	37.5-325	mg
TRAMADOL HCL/DIETARY SUPPLEMENT,MISC. CB.11	Theratramadol-60	oral	combo pack	50	mg
TRAMADOL HCL/DIETARY SUPPLEMENT,MISC. CB.11	Theratramadol-90	oral	combo pack	50	mg
TRAMADOL HCL/GLUCOSAMINE SULFATE	Synapryn	oral	suspension fo	10-5	mg/mL

Appendix E: Specifications for Opioid Analgesics Prescribing Trends: Drug Screen Metrics (to16_cap_mpl1r_wp022_nsdp_v01)

The Opioid Analgesics Prescribing Trends Workgroup has requested the use of the Cohort Identification and Descriptive Analysis (CIDA) Tool, version 2.0.7, to investigate opioid use and drug screen metrics in the Mini-Sentinel Distributed Database (MSDD). The query period was from January 1, 2009 to December 31, 2013, and the enrollment gap was set at 45 days. Age groups were split as follows: 0-11, 12-17, 18-24, 25-34, 35-44, 45-54, 55-64. In total, 48 scenarios were examined. This report contains results for scenarios 25-48 only. Results for scenarios 1-24 are contained in Report 1.

Enrollment Gap 45 days
 Age Groups 0-11, 12-17, 18-24, 25-34, 35-44, 45-54, 55-64 years
 Query Period 1/1/2009 - 12/31/2013
 Coverage Requirement Drug and Medical Coverage
 Same Day Dispensing Processing Maximum days supplied, Add amount supplied
 Stockpiling Grouping Generic name and dose

Scenario	Pre-exposure Enrollment Requirement	Drug/Exposure								Inclusion/Exclusion Criteria				Event/Outcome
		Incident exposure	Incident w/ respect to:	Washout (days)	Cohort Definition	Minimum Episode Duration	Minimum Days Supplied	Episode Gap	Episode Extension Period	Inclusion/Exclusion Condition	Include or Exclude	Lookback Start	Lookback End	Event/Outcome
1	183	ER/LA opioid analgesics	ER/LA opioid analgesics	183	02	1	1	10	0	Opioid poisoning	Exclude	-183	-1	Dummy
2	183	ER/LA opioid analgesics	ER/LA opioid analgesics	183	02	1	1	10	0	Opioid poisoning IR opioid use	Exclude Exclude	-183 -60	-1 -1	Dummy
3	183	ER/LA opioid analgesics	ER/LA opioid analgesics	183	02	1	1	10	0	Opioid poisoning Drug screen	Exclude Include	-183 -30	-1 0	Dummy
4	183	ER/LA opioid analgesics	ER/LA opioid analgesics	183	02	1	1	10	0	Opioid poisoning IR opioid use Drug screen	Exclude Exclude Include	-183 -60 -30	-1 -1 0	Dummy
5	183	ER/LA opioid analgesics	ER/LA opioid analgesics	183	02	1	1	10	0	Opioid poisoning Drug screen	Exclude Include	-183 1	-1 183	Dummy
6	183	ER/LA opioid analgesics	ER/LA opioid analgesics	183	02	1	1	10	0	Opioid poisoning IR opioid use Drug screen	Exclude Exclude Include	-183 -60 1	-1 -1 183	Dummy
7	183	ER/LA opioid analgesics	ER/LA opioid analgesics	183	02	84	84	10	0	Opioid poisoning	Exclude	-183	-1	Dummy
8	183	ER/LA opioid analgesics	ER/LA opioid analgesics	183	02	84	84	10	0	Opioid poisoning IR opioid use	Exclude Exclude	-183 -60	-1 -1	Dummy
9	183	ER/LA opioid analgesics	ER/LA opioid analgesics	183	02	84	84	10	0	Opioid poisoning Drug screen	Exclude Include	-183 -30	-1 0	Dummy
10	183	ER/LA opioid analgesics	ER/LA opioid analgesics	183	02	84	84	10	0	Opioid poisoning IR opioid use Drug screen	Exclude Exclude Include	-183 -60 -30	-1 -1 0	Dummy

11	183	ER/LA opioid analgesics	ER/LA opioid analgesics	183	02	84	84	10	0	Opioid poisoning Drug screen	Exclude Include	-183 1	-1 183	Dummy
12	183	ER/LA opioid analgesics	ER/LA opioid analgesics	183	02	84	84	10	0	Opioid poisoning IR opioid use Drug screen	Exclude Exclude Include	-183 -60 1	-1 -1 183	Dummy
13	90	ER/LA opioid analgesics	ER/LA opioid analgesics	90	02	1	1	10	0	Opioid poisoning	Exclude	-90	-1	Dummy
14	90	ER/LA opioid analgesics	ER/LA opioid analgesics	90	02	1	1	10	0	Opioid poisoning IR opioid use	Exclude Exclude	-90 -60	-1 -1	Dummy
15	90	ER/LA opioid analgesics	ER/LA opioid analgesics	90	02	1	1	10	0	Opioid poisoning Drug screen	Exclude Include	-90 -30	-1 0	Dummy
16	90	ER/LA opioid analgesics	ER/LA opioid analgesics	90	02	1	1	10	0	Opioid poisoning IR opioid use Drug screen	Exclude Exclude Include	-90 -60 -30	-1 -1 0	Dummy
17	90	ER/LA opioid analgesics	ER/LA opioid analgesics	90	02	1	1	10	0	Opioid poisoning Drug screen	Exclude Include	-90 1	-1 183	Dummy
18	90	ER/LA opioid analgesics	ER/LA opioid analgesics	90	02	1	1	10	0	Opioid poisoning IR opioid use Drug screen	Exclude Exclude Include	-90 -60 1	-1 -1 183	Dummy
19	90	ER/LA opioid analgesics	ER/LA opioid analgesics	90	02	84	84	10	0	Opioid poisoning	Exclude	-90	-1	Dummy
20	90	ER/LA opioid analgesics	ER/LA opioid analgesics	90	02	84	84	10	0	Opioid poisoning IR opioid use	Exclude Exclude	-90 -60	-1 -1	Dummy
21	90	ER/LA opioid analgesics	ER/LA opioid analgesics	90	02	84	84	10	0	Opioid poisoning Drug screen	Exclude Include	-90 -30	-1 0	Dummy
22	90	ER/LA opioid analgesics	ER/LA opioid analgesics	90	02	84	84	10	0	Opioid poisoning IR opioid use Drug screen	Exclude Exclude Include	-90 -60 -30	-1 -1 0	Dummy
23	90	ER/LA opioid analgesics	ER/LA opioid analgesics	90	02	84	84	10	0	Opioid poisoning Drug screen	Exclude Include	-90 1	-1 183	Dummy
24	90	ER/LA opioid analgesics	ER/LA opioid analgesics	90	02	84	84	10	0	Opioid poisoning IR opioid use Drug screen	Exclude Exclude Include	-90 -60 1	-1 -1 183	Dummy
25	183	ERO opioid analgesics	ER/LA opioid analgesics	183	02	1	1	10	0	Opioid poisoning	Exclude	-183	-1	Dummy
26	183	ERO opioid analgesics	ER/LA opioid analgesics	183	02	1	1	10	0	Opioid poisoning IR opioid use	Exclude Exclude	-183 -60	-1 -1	Dummy
27	183	ERO opioid analgesics	ER/LA opioid analgesics	183	02	1	1	10	0	Opioid poisoning Drug screen	Exclude Include	-183 -30	-1 0	Dummy

28	183	ERO opioid analgesics	ER/LA opioid analgesics	183	02	1	1	10	0	Opioid poisoning	Exclude	-183	-1	Dummy
										IR opioid use	Exclude	-60	-1	
										Drug screen	Include	-30	0	
29	183	ERO opioid analgesics	ER/LA opioid analgesics	183	02	1	1	10	0	Opioid poisoning	Exclude	-183	-1	Dummy
										Drug screen	Include	1	183	
										Opioid poisoning	Exclude	-183	-1	
30	183	ERO opioid analgesics	ER/LA opioid analgesics	183	02	1	1	10	0	IR opioid use	Exclude	-60	-1	Dummy
										Drug screen	Include	1	183	
										Opioid poisoning	Exclude	-183	-1	
31	183	ERO opioid analgesics	ER/LA opioid analgesics	183	02	84	84	10	0	Opioid poisoning	Exclude	-183	-1	Dummy
32	183	ERO opioid analgesics	ER/LA opioid analgesics	183	02	84	84	10	0	Opioid poisoning	Exclude	-183	-1	Dummy
33	183	ERO opioid analgesics	ER/LA opioid analgesics	183	02	84	84	10	0	Opioid poisoning	Exclude	-183	-1	Dummy
										Drug screen	Include	-30	0	
										Opioid poisoning	Exclude	-183	-1	
34	183	ERO opioid analgesics	ER/LA opioid analgesics	183	02	84	84	10	0	IR opioid use	Exclude	-60	-1	Dummy
										Drug screen	Include	-30	0	
										Opioid poisoning	Exclude	-183	-1	
35	183	ERO opioid analgesics	ER/LA opioid analgesics	183	02	84	84	10	0	Opioid poisoning	Exclude	-183	-1	Dummy
										Drug screen	Include	1	183	
										Opioid poisoning	Exclude	-183	-1	
36	183	ERO opioid analgesics	ER/LA opioid analgesics	183	02	84	84	10	0	IR opioid use	Exclude	-60	-1	Dummy
										Drug screen	Include	1	183	
										Opioid poisoning	Exclude	-183	-1	
37	90	ERO opioid analgesics	ER/LA opioid analgesics	90	02	1	1	10	0	Opioid poisoning	Exclude	-90	-1	Dummy
38	90	ERO opioid analgesics	ER/LA opioid analgesics	90	02	1	1	10	0	Opioid poisoning	Exclude	-90	-1	Dummy
										IR opioid use	Exclude	-60	-1	
										Opioid poisoning	Exclude	-90	-1	
39	90	ERO opioid analgesics	ER/LA opioid analgesics	90	02	1	1	10	0	Drug screen	Include	-30	0	Dummy
										Opioid poisoning	Exclude	-90	-1	
										IR opioid use	Exclude	-60	-1	
40	90	ERO opioid analgesics	ER/LA opioid analgesics	90	02	1	1	10	0	Drug screen	Include	-30	0	Dummy
										Opioid poisoning	Exclude	-90	-1	
										IR opioid use	Exclude	-60	-1	
41	90	ERO opioid analgesics	ER/LA opioid analgesics	90	02	1	1	10	0	Opioid poisoning	Exclude	-90	-1	Dummy
										Drug screen	Include	1	183	
										Opioid poisoning	Exclude	-90	-1	
42	90	ERO opioid analgesics	ER/LA opioid analgesics	90	02	1	1	10	0	IR opioid use	Exclude	-60	-1	Dummy
										Drug screen	Include	1	183	
										Opioid poisoning	Exclude	-90	-1	
43	90	ERO opioid analgesics	ER/LA opioid analgesics	90	02	84	84	10	0	Opioid poisoning	Exclude	-90	-1	Dummy
44	90	ERO opioid analgesics	ER/LA opioid analgesics	90	02	84	84	10	0	Opioid poisoning	Exclude	-90	-1	Dummy
										IR opioid use	Exclude	-60	-1	
										Opioid poisoning	Exclude	-90	-1	
45	90	ERO opioid analgesics	ER/LA opioid analgesics	90	02	84	84	10	0	Drug screen	Include	-30	0	Dummy
										Opioid poisoning	Exclude	-90	-1	
										IR opioid use	Exclude	-60	-1	

46	90	ERO opioid analgesics	ER/LA opioid analgesics	90	02	84	84	10	0	Opioid poisoning	Exclude	-90	-1	Dummy
										IR opioid use	Exclude	-60	-1	
										Drug screen	Include	-30	0	
47	90	ERO opioid analgesics	ER/LA opioid analgesics	90	02	84	84	10	0	Opioid poisoning	Exclude	-90	-1	Dummy
										Drug screen	Include	1	183	
48	90	ERO opioid analgesics	ER/LA opioid analgesics	90	02	84	84	10	0	Opioid poisoning	Exclude	-90	-1	Dummy
										IR opioid use	Exclude	-60	-1	
										Drug screen	Include	1	183	

National Drug Codes (NDCs) checked against First Data Bank's "National Drug Data File (NDDF®) Plus"

International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) diagnosis and procedure codes checked against "Ingenix 2012 ICD-9-CM Data File" provided by OptumInsight

Healthcare Common Procedure Coding System (HCPCS) codes checked against "Optum 2012 HCPCS Level II Data File" provided by OptumInsight

Current Procedural Terminology (CPT) codes checked against "Optum 2012 Current Procedure Codes & Relative Values Data File" provided by OptumInsight

Appendix F: List of Dates of Available Data for Each Data Partner as of Request Send Date (July 29, 2015)

DP ID	Start Date	End Date
DP001	1/1/2009	12/31/2013
DP002	1/1/2009	12/31/2013
DP003	1/1/2009	12/31/2013
DP004	1/1/2009	12/31/2013
DP005	1/1/2009	12/31/2013
DP006	1/1/2009	12/31/2013
DP007	1/1/2009	12/31/2012
DP008	1/1/2009	12/31/2013
DP009	1/1/2009	12/31/2013
DP010	1/1/2009	12/31/2013
DP011	1/1/2009	12/31/2013
DP012	1/1/2009	12/31/2013
DP013	1/1/2009	6/30/2012
DP014	1/1/2009	12/31/2013
DP015	1/1/2009	12/31/2013